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Abstract 
Cytotoxic chemotherapy is an effective treatment for invasive breast cancer. However, experimental 
studies in mice also suggest pro-metastatic effects of chemotherapy. Primary tumours release 
extracellular vesicles (EVs), including exosomes, that can facilitate the seeding and growth of 
metastatic cancer cells in distant organs, but the effects of chemotherapy on tumour-derived EVs 
remain unclear. Here we show that two classes of cytotoxic drugs broadly employed in pre-operative 
(neoadjuvant) breast cancer therapy, taxanes and anthracyclines, elicit tumour-derived EVs with 
enhanced pro-metastatic capacity. Chemotherapy-elicited EVs are enriched in annexin-A6 (ANXA6), 
a Ca2+-dependent protein that promotes NF-kB-dependent endothelial cell activation, Ccl2 induction, 
and Ly6C+CCR2+ monocyte expansion in the pulmonary pre-metastatic niche to facilitate the 
establishment of lung metastasis. Genetic inactivation of Anxa6 in cancer cells, or Ccr2 in host cells, 
blunts the pro-metastatic effects of chemotherapy-elicited EVs. ANXA6 is detected, and potentially 
enriched, in the circulating EVs of breast cancer patients undergoing neoadjuvant chemotherapy.  
 
Introduction 
Neoadjuvant chemotherapy may provide long-term clinical benefit in patients diagnosed with 
invasive breast cancer, especially when the primary tumour fully regresses before surgery 1-6. 
However, the therapeutic benefits of neoadjuvant chemotherapy may be limited by tumour-
promoting host responses that are induced by certain cytotoxic drugs 7. Several reports have 
documented pro-metastatic effects of cytotoxic agents in mouse mammary tumour models 8-13. For 
example, paclitaxel (PTX), a microtubule-stabilizing drug often used in breast cancer therapy 5,6, was 
reported to enhance expression of vascular-endothelial growth factor receptor-1 (VEGFR1) on 
pulmonary endothelial cells to facilitate cancer-cell adhesion and subsequent metastasis 13. Both 
PTX and doxorubicin (DOX) Ð an anthracycline also used in breast cancer therapy 5,6 Ð increased 
the ability of perivascular TIE2+ macrophages 14-16 to promote cancer-cell intravasation in primary 
mammary tumours, resulting in heightened pulmonary metastasis 8,12. Collectively, pre-clinical data 
in mouse models suggest that the pro-metastatic capacity of certain chemotherapies may involve 
facilitation of both cancer cell intravasation in primary tumours and extravasation to secondary, 
metastatic sites. 
Primary tumours release extracellular vesicles (EVs) that can modulate the biology of distant 
organ niches to enhance seeding and growth of metastatic cancer cells 17-24. In this study, we 
examined the effects of PTX and DOX on the release, properties and pro-metastatic potential of 
tumour-derived EVs in mouse models of chemoresistant breast cancer. 
 
Results 
PTX enhances pulmonary metastasis in mouse mammary tumour models 
We examined the effects of PTX on metastasis in two mouse breast cancer models: transgenic 
MMTV-PyMT mice (FVB/n background), which develop multifocal mammary tumours 25-27, and 
  
immunodeficient Rag1−/− (C57BL/6 background) or Swiss nu/nu mice challenged with 4T1 cancer 
cells 28. In order to trace metastasis, the 4T1 cells were modified to express a fluorescent CD9-
mCherry (mCh) fusion protein targeted to cellular membranes; in some experiments, 4T1 cells were 
further modified to express a human ERBB2 (HER2) transgene 29. The 4T1 tumour studies used 
immunodeficient mice to avoid potential anti-tumour immune responses against mCh or HER2.  
Tumour-bearing mice received 3 doses of PTX (10 mg/kg) or vehicle (cremophor, CREMO) 
before analysis (Fig. 1a). PTX had modest, if any, inhibitory activity on the growth of primary 
mammary tumours in both MMTV-PyMT and 4T1 models (Fig. 1b-e). However, it increased 
pulmonary tumour deposits in a fraction of the mice, in line with previous findings 8-12. In particular, 
PTX increased the incidence (Fig. 1f, g) and mean size (Fig. 1f, h, i) of spontaneous metastases in 
lungs of MMTV-PyMT mice, as well as the seeding of mCh+ 4T1 cancer cells in the lungs of tumour-
bearing Rag1−/− mice (Fig. 1j-k), compared to vehicle. PTX also enhanced pulmonary seeding of 
mCh+HER2+ cancer cells in some tumour-bearing Swiss nu/nu mice (Fig. 1l), although it did not 
augment the frequency of mCh+HER2+ cancer cells in the systemic circulation (Fig. 1m). Together, 
these results indicate that PTX may augment, rather than limit, lung metastasis in mouse models of 
chemoresistant breast cancer.  
 
Chemotherapy-elicited EVs promote mammary tumour metastasis in mice 
Tumour-derived EVs facilitate metastasis of primary tumours by altering the properties of pre-
metastatic niche-associated host cells 17-24. In order to gauge the participation of tumour-derived EVs 
in PTX-induced mammary tumour metastasis, we used sequential ultracentrifugation to isolate EVs 
30,31 from cell culture media of unmodified 4T1 cancer cells treated with either PTX or CREMO (PTX-
EV and CREMO-EV, respectively). The resulting preparations were highly enriched in small EVs, as 
shown by both transmission electron microscopy (TEM; Fig. 2a) and nanoparticle tracking analysis 
(NTA; Supplementary Fig. 1a). Also, the EV-associated proteins CD9, CD81 and syntenin-1 were 
enriched in EVs compared to producer cells, as demonstrated by Western blotting analysis 
(Supplementary Fig. 1b). Although we cannot rule out co-purification of small apoptotic bodies, the 
physical and molecular properties of the preparations are consistent with bona fide EVs 30-32 with 
mode size comprised between 100 and 150 nm. 
 We pre-conditioned immunocompetent Balb/c mice with either PTX-EV or CREMO-EV (two 
doses, each corresponding to about 4x109 EVs; Supplementary Fig. 1c), followed by intravenous 
injection of 4T1 cells (Fig. 2b). In this lung colonization assay, PTX-EV increased the number of 
metastatic lung nodules compared to CREMO-EV (Fig. 2c). We then asked if PTX could also affect 
the pro-metastatic capacity of EVs released from an intact tumour microenvironment. To this aim, 
we treated MMTV-PyMT mice with PTX or CREMO (see Fig. 1a above), excised mammary tumours 
three days after the last dose, and cultured tumour-derived cell suspensions for 48h in order to 
isolate EVs from conditioned media (Fig. 2d). We assessed the purity and properties of EV 
preparations by TEM (Supplementary Fig. 1d), NTA (Supplementary Fig. 1e-f), and Western 
  
blotting analysis (Supplementary Fig. 1g), and found no obvious differences between PTX-EV and 
CREMO-EV. We then pre-conditioned immunocompetent FVB/n mice with either EV preparation 
(Fig. 2b), followed by the intravenous injection of freshly isolated MMTV-PyMT tumour-derived cells. 
Similar to results obtained with 4T1 cells, PTX-EV increased the number of metastatic nodules in 
this MMTV-PyMT-based lung colonization assay (Fig. 2e).  
 Anthracyclines are broadly employed in neoadjuvant breast cancer therapy 1,5,6. DOX, a lead 
anthracycline, was reported previously to modify the microenvironment of primary mammary 
tumours to potentially facilitate metastasis 8,33. We treated MMTV-PyMT mice with DOX or vehicle 
(PBS) and purified tumour-derived DOX-EV and PBS-EV, respectively, according to the method 
shown in Fig. 2d. Similar to results obtained with PTX-EV, DOX-EV enhanced metastasis, 
compared to PBS-EV, in an MMTV-PyMT-based lung colonization assay (Fig. 2f). Of note, neither 
PTX nor DOX directly increased metastasis in this assay; rather, the free drugs limited, or even 
abated, lung colonization by MMTV-PyMT tumour-derived cells (Fig. 2g). These results indicate that 
chemotherapy-elicited, tumour-derived EVs mediate the pro-metastatic activity of the cytotoxic 
drugs. 
 
PTX-elicited EVs facilitate tumour colonization in a zebrafish embryo model 
Because tumour-derived EVs cannot be isolated from mouse plasma in amounts sufficient to 
perform EV transfer experiments in mice, we examined the pro-metastatic capacity of circulating 
PTX-EV in a zebrafish embryo model. In this system, cancer cells injected into the circulation 
extravasate to, and colonize the caudal haematopoietic area (CHA) of the tail of embryos; these 
events can be imaged by confocal microscopy, as embryos are translucent 34,35. We found that PTX-
EV isolated from plasma of 4T1-mCh tumour-bearing Rag1−/− mice (Fig. 2h) enhanced CHA 
colonization by human MDA-MB-435 melanoma cells stably expressing cyan fluorescent protein 
(CFP), compared to CREMO-EV (Fig. 2i-l). Of note, free PTX did not facilitate CHA colonization by 
cancer cells in the same assay. 
  
PTX modulates EV release from cancer cells 
We then examined the effects of chemotherapy on EV release from cancer cells. PTX increased the 
release of EVs from both mouse and human mammary carcinoma cell lines (Supplementary Fig. 
2a-c). It also increased mCh fluorescence in the blood of mice carrying 4T1-mCh tumours 
(Supplementary Fig. 2d-f). In these experiments, mCh fluorescence was associated with bona fide 
EVs (Supplementary Fig. 2g-i) and was resistant to proteolysis (Supplementary Fig. 2j-k), 
indicating intra-vesicular localization of the CD9-mCh fusion protein.  
 Cytotoxic agents, including PTX, promote cancer cell death in a dose-dependent manner 
(Supplementary Fig. 2a and Supplementary Fig. 3a-b). Although drug-induced cell stress may 
influence release of EVs and other microvesicles from pre-apoptotic cells 32, PTX-induced EV 
release from 4T1 cells was apoptosis-independent (Supplementary Fig. 3c).  
  
 RAB GTPases control EV biogenesis and release in mammalian cells 36,37. Accordingly, both 
basal and PTX-induced EV release were reduced in Rab27a-deficient 4T1 cells (Supplementary 
Fig. 3d-g). PTX may enhance EV release from cancer cells by enforcing the trafficking of 
intracellular vesicles to plasma membranes (Supplementary Fig. 3h); this process may involve the 
association of RAB27A with microtubules, which are stabilized by taxanes 38. We observed 
enhanced EV release also from 4T1 cells exposed to a different taxane, docetaxel (Supplementary 
Fig. 3i). Conversely, DOX did not promote EV release from mammary carcinoma cells 
(Supplementary Fig. 3j, k). Therefore, whereas taxanes may increase mammary tumour 
metastasis by enhancing both the release and pro-metastatic properties of tumour-derived EVs, 
anthracyclines may do so by specifically reinforcing the pro-metastatic features of the EVs. 
 
Chemotherapy-elicited EVs are enriched in ANXA6 
Enhanced pro-metastatic capacity of chemotherapy-elicited EVs may depend on their protein 
repertoire. We performed proteomic analysis of 4T1-derived PTX-EV and CREMO-EV using liquid 
chromatography-tandem mass spectrometry (LC-MS/MS). Unsupervised clustering analysis of the 
EV proteomes (Fig. 3a) revealed substantial differences (Supplementary Table 1). Over-
represented proteins in PTX-EVs included annexin-A6 (ANXA6; Fig. 3b), a Ca2+-binding membrane-
associated protein (Fig. 3c). ANXA6 controls membrane trafficking and cell signalling 39, and has 
been previously implicated in both the positive and negative regulation of cancer cell invasion 40-42. 
Validation experiments by Western blotting revealed that ANXA6 was more robustly detected in 
PTX-EV compared to the producer 4T1 cells or CREMO-EV (Fig. 3d). Notably, both PTX and DOX 
promoted ANXA6 loading into EVs of 4T1 cells and the MMTV-PyMT tumour-derived cell line PyMT-
IK1 (Fig. 3e).  
 Both taxanes 43 and anthracyclines 44 augment intracellular calcium ion levels. Interestingly, 
chemotherapy-induced ANXA6 loading into EVs was Ca2+-dependent (Fig. 3f-i), whereas EV 
release per se was Ca2+-independent (Fig. 3j). Western blotting and density gradient fractionation of 
EVs 30 purified from medium conditioned by 4T1 or 4T1-mCh cells confirmed that ANXA6 was 
associated with bona fide EVs (Supplementary Fig. 1b above and Supplementary Fig. 4a-b) and, 
in particular, with the inner leaflet of EVs (Supplementary Fig. 4c-d). Neither PTX nor DOX 
increased ANXA6 in EVs released by non-transformed cells, such as mouse primary bone marrow 
dendritic cells and embryonic fibroblasts (Supplementary Fig. 4e-h). 
 
EV-associated ANXA6 promotes mammary tumour metastasis 
The aforementioned results suggested a potential role for ANXA6 in modulating chemotherapy-
induced mammary tumour metastasis. To test this possibility, we generated Anxa6 knockout (KO) 
4T1-mCh cells using CRISPR/Cas9 technology (Fig. 4a). We obtained two Anxa6-deficient clones 
(Fig. 4b), which were used in subsequent experiments. ANXA6 was exhaustively depleted from 
Anxa6-KO 4T1-mCh-derived EVs treated with either CREMO or PTX (Fig. 4c). ANXA6 deficiency in 
  
4T1-mCh cells did not impair the enhancement of EV release by PTX (Fig. 4d); furthermore, Anxa6-
proficient (WT) and KO EVs were indistinguishable based on TEM (Fig. 4e) and NTA (Fig. 4f-g).  
 We then isolated Anxa6-WT and KO EVs from 4T1-mCh cells treated in vitro with either PTX or 
DOX (or the appropriate vehicle) to pre-condition Rag1−/− mice before the intravenous injection of 
4T1-mCh cells, according to a lung colonization assay (see Fig. 2b above). Remarkably, ANXA6 
deficiency in PTX-EV or DOX-EV disrupted their capacity to facilitate lung colonization by 4T1-mCh 
cells (Fig. 4h-i). The depletion of ANXA6 from 4T1 cells (Supplementary Fig. 4i) did not alter 
loading of PTX or DOX into EVs (Supplementary Fig. 4j), arguing against the possibility that 
ANXA6-deficient EVs had compromised pro-metastatic capacity owing to changes in intravesicular 
drug levels, which were negligible irrespective of ANXA6 status (Supplementary Fig. 4k).  
 
PTX induces CCL2 expression and Ly6C+ monocyte expansion in lungs of mammary tumour-
bearing mice 
We analysed expression of cytokines known to facilitate mammary tumour metastasis, such as 
CCL2, CXCL12, CSF1 and ANGPT2 45, in lungs of tumour-free and 4T1-mCh tumour-bearing 
Rag1−/− mice treated with either PTX or CREMO. PTX significantly increased Ccl2 expression both 
at the mRNA (Fig. 5a) and protein (Fig. 5b) level in lungs of 4T1-mCh tumour-bearing but not 
tumour-free mice.  
 CCL2 was reported previously to enhance Ly6C+CCR2+ monocyte-assisted metastasis of 
mammary tumours 46-49. Consistent with upregulation of CCL2, PTX increased the relative 
abundance of Ly6C+ monocytes in lungs of 4T1-mCh tumour-bearing Rag1−/− mice, 4T1 tumour-
bearing Balb/c mice, 4T1-mCh/HER2 tumour-bearing Swiss nu/nu mice, and transgenic MMTV-
PyMT mice, compared to vehicle (Fig. 5c-g). Conversely, PTX did not alter the relative abundance 
of Ly6C+ monocytes in the lungs of tumour-free mice (Fig. 5h-i). These results indicate that signals 
emanating from primary tumours are required for PTX-induced upregulation of CCL2 and expansion 
of Ly6C+ monocytes in lungs. 
 
Chemotherapy-elicited EVs induce pulmonary CCL2 expression and Ly6C+ monocyte 
expansion 
We examined whether the effects of PTX on CCL2 and Ly6C+ monocytes were dependent on EVs. 
To this aim, we performed pre-conditioning studies with EVs in tumour-free mice (Fig. 6a). PTX-EV 
isolated from 4T1 or 4T1-mCh cells increased lung Ccl2 expression in Balb/c and Rag1−/− tumour-
free mice, respectively (Fig. 6b, c). We obtained similar results when we pre-conditioned tumour-
free FVB/n mice with PTX-EV isolated ex vivo from MMTV-PyMT tumour-derived cells (see Fig. 2d 
above, and Fig. 6d). Paralleling Ccl2 expression, the relative abundance of lung Ly6C+CCR2+ 
monocytes increased in response to PTX-EV (Fig. 6e-i). Notably, both Ccl2 expression and Ly6C+ 
monocytes were also increased in response to DOX-EV isolated ex vivo from MMTV-PyMT tumour-
derived cells (Fig. 6j-k).  
  
 
The pro-metastatic capacity of chemotherapy-elicited EVs is dependent on Ly6C+CCR2+ 
monocytes and ANXA6 
To explore the functional involvement of Ly6C+CCR2+ monocytes in PTX-EV-mediated pulmonary 
metastasis, we performed pre-conditioning experiments with EVs in Ccr2 KO mice (C57Bl/6 
background), which have impaired monocyte-assisted mammary cancer metastasis 49. Whereas 
PTX-EV derived from E0771-LG mouse mammary carcinoma cells enhanced pulmonary seeding of 
firefly luciferase-expressing E0771-LG:Fl cells in Ccr2 WT mice, they failed to do so in Ccr2 KO 
mice (Fig. 6l). Interestingly, Ccr2 was upregulated in Ly6C+ monocytes, but not other myeloid cells, 
that were sorted from the lungs of tumour-free FVB/n mice pre-conditioned with PTX-EV (Fig. 6m). 
These data strongly argue that Ly6C+CCR2+ monocytes mediate EV-induced, pulmonary mammary 
cancer metastasis.   
Because Anxa6 KO PTX-EV failed to enhance pulmonary colonization by 4T1-mCh cells 
(see Fig. 4h-i above), we asked whether PTX-EV-mediated effects on pulmonary CCL2 expression 
and Ly6C+ monocyte expansion were also dependent on ANXA6 in EVs. ANXA6 deficiency in PTX-
EV isolated from 4T1-mCh cells prevented Ccl2 and Ccr2 upregulation (Fig. 6n) and the increase of 
Ly6C+ monocytes (Fig. 6o) in the lungs of Rag1−/− mice. Together, these results indicate that 
chemotherapy-induced enrichment of ANXA6 in mammary tumour-derived EVs supports a pro-
metastatic cascade in the lung that is dependent on local Ly6C+ monocyte expansion. 
 
Chemotherapy-elicited EVs promote inflammatory EC activation through ANXA6 transfer 
The internalization of breast cancer-derived EVs into lung endothelial cells (ECs) may influence the 
initial steps of pulmonary metastasis by altering the biology of those cells in the pre-metastatic niche 
24,50. We observed increased proportions of lung ECs displaying mCh fluorescence after treating 
4T1-mCh tumour-bearing Rag1−/− or 4T1-mCh/HER2 tumour-bearing Swiss nu/nu mice with PTX, 
compared to CREMO (Fig. 7a-c).  
 Increased mCh fluorescence in lung ECs may denote internalization of tumour-derived EVs, a 
process that can occur through EV-cell fusion 51. We then used a murine EC line, bEnd.3, to study 
effects of EVs on ECs. bEnd.3 cells internalized mCh+ EVs in a dose-dependent manner 
(Supplementary Fig. 5a, b); interestingly, bEnd.3 cells exposed to medium conditioned by PTX-
treated 4T1-mCh or PyMT-IK1-mCh cancer cells displayed higher mCh fluorescence than bEnd.3 
cells exposed to medium conditioned by CREMO-treated cells (Supplementary Fig. 5c). Moreover, 
PTX-EV from either 4T1-mCh or PyMT-IK1-mCh cells were internalized by bEnd.3 cells more 
efficiently than matched amounts of CREMO-EV (Supplementary Fig. 5d). Finally, uptake of EVs 
by bEnd.3 cells was independent of ANXA6 (Supplementary Fig. 5e), suggesting that other 
molecules (Supplementary Table 1), such as integrins 38, could mediate the preferential uptake of 
PTX-EV. 
PTX-EV isolated from either 4T1-mCh or PyMT-IK1-mCh cells transferred ANXA6 (and mCh) 
  
to bEnd.3 cells that were made Anxa6-deficient using CRISPR/Cas9 (Fig. 7d and Supplementary 
Fig. 6a-b). Duolink proximity ligation assay, which enables imaging of protein pairs that co-localize 
within 40 nm, indicated that PTX-EV-mediated transfer of ANXA6 to Anxa6 KO bEnd.3 cells was 
conducive to ANXA6 co-localization with the NF-kB subunit p65 (Fig. 7e and Supplementary Fig. 
6c-d), consistent with the ability of ANXA6 to interact with p65 (Ref 52). Of note, matched doses of 
CREMO-EV did not reveal detectable ANXA6/p65 proximity in the same assay, possibly because 
PTX-EV fuse more efficiently than CREMO-EV with bEnd.3 cells (see Supplementary Fig. 5c-e 
above) and contain higher amounts of ANXA6 than CREMO-EV (see Fig. 3d-j above).  
NF-kB (p65/Rela) activates Ccl2 transcription 53. In order to gain insight into a potential 
mechanistic link between ANXA6 transfer to ECs and Ccl2 upregulation, we generated Rela (p65) 
KO bEnd.3 cells, which had defective NF-kB activation and Ccl2 expression (Fig. 7f and 
Supplementary Fig. 6e). PTX-EV isolated from 4T1-mCh cells failed to induce NF-kB activation 
(Fig. 7g) and Ccl2 upregulation (Fig. 7h) in Rela KO bEnd.3 cells. Conversely, PTX-EV isolated 
from 4T1-mCh or PyMT-IK1 cells increased NF-kB activity and Ccl2 expression in Rela-proficient 
bEnd.3 cells; notably, these responses required ANXA6 in EVs. Accordingly, Anxa6 KO bEnd.3 cells 
had defective NF-kB activation and Ccl2 transcription in response to tumour-necrosis factor (TNF) 
compared to Anxa6 WT cells; of note, neither Csf1 nor Cxcl12 were regulated by ANXA6 
(Supplementary Fig. 6f-i). Similar to PTX-EV, DOX-EV from 4T1 cells also increased Ccl2 
transcript levels (Fig. 7i) and NF-kB activity (Fig. 7j) in bEnd.3 cells. Therefore, EV-associated 
ANXA6 triggers an NF-kB-dependent pro-inflammatory response in ECs. 
We then examined whether PTX-EV could activate Ccl2 transcription in lung ECs, which are 
a source of CCL2 in mammary tumour-bearing mice 54. We used fluorescence-activated cell sorting 
(FACS) to isolate lung ECs of tumour-free FVB/n mice pre-conditioned with MMTV-PyMT tumour-
derived PTX-EV or CREMO-EV (see Fig. 2d above) and found enhanced Ccl2 expression in lung 
ECs exposed to PTX-EV (Fig. 7k). Taken together, these findings suggest that chemotherapy-
elicited tumour EVs promote pro-inflammatory EC activation, CCL2 upregulation, Ly6C+ monocyte 
accumulation, and tumour colonization at metastatic sites through a mechanism involving horizontal 
transfer of EV-associated ANXA6 to the pulmonary endothelium. 
 
Chemotherapy-elicited EVs display broad cellular tropism in tumour-bearing mice  
Besides ECs, other lung-resident cells may mediate metastasis in response to chemotherapy-
induced EVs. Indeed, CD11b+Gr1Ð lung macrophages/monocytes also internalized mCh+ EVs in 
PTX-treated, 4T1-mCh Rag1−/− or 4T1-mCh/HER2 Swiss nu/nu tumour-bearing mice 
(Supplementary Fig. 7a-b). Moreover, PTX-EV isolated from MMTV-PyMT tumour-derived cells 
upregulated interleukin-6 (Il6) expression in the lung (Supplementary Fig. 7c) and, specifically, 
lung-associated non-alveolar macrophages (Supplementary Fig. 7d) of tumour-free FVB/n mice; of 
note, IL-6 was previously implicated in chemotherapy resistance 55 and macrophage-assisted 
mammary tumour metastasis 47,56. 
  
 Finally, PTX-EV transferred mCh to liver sinusoidal ECs more efficiently than CREMO-EV 
(Supplementary Fig. 7e, f), suggesting that chemotherapy-elicited EVs might also promote breast 
cancer metastasis to the liver. However, the rapid growth kinetics of both primary tumours and 
pulmonary metastasis in the breast cancer models employed in our study complicate the 
assessment of slow-growing liver metastases. 
 
ANXA6 is detected in circulating EVs of breast cancer patients undergoing neoadjuvant 
chemotherapy 
We finally investigated effects of chemotherapy on EV-associated ANXA6 in human breast cancer 
cells and patients with breast cancer. Both PTX and DOX increased ANXA6 protein levels in EVs 
released by human MDA-MB-231 breast cancer cells (Fig. 8a). Furthermore, EVs purified from the 
plasma of breast cancer patients undergoing neoadjuvant chemotherapy (Supplementary Table 2 
and Fig. 8b) had increased ANXA6 content by LC-MS/MS in five out of six cases, compared to pre-
treatment levels (Fig. 8c, Supplementary Fig. 8 and Supplementary Table 3). Because we could 
isolate limited amounts of EVs from each sample, we were only able to verify the LC-MS/MS data by 
Western blotting in one case (patient #56; Fig. 8d). Notably, ANXA6 levels in the EVs decreased at 
the end of neoadjuvant therapy in the patients who achieved a partial or complete response (five out 
of six), probably reflecting shrinkage of the tumour in response to chemotherapy. Also, the finding 
that EV-associated ANXA6 levels increased on-therapy in one patient with progressive disease 
(#52) strongly suggested that EV-associated ANXA6 was, in fact, of cancer cell origin. While limited, 
these data support the notion that chemotherapy augments ANXA6 levels in circulating EVs of 
patients with breast cancer. 
 
Discussion 
Neoadjuvant chemotherapy improves the management of invasive breast cancer by inducing 
pathological complete responses associated with significantly reduced risk of recurrence in a 
fraction of the patients 1-6. However, therapy-induced host responses 7, such as those described in 
our study, may limit the benefits of pre-operatory treatments in some patients. It is tempting to 
speculate that human primary breast tumours that fail to readily regress on neoadjuvant 
chemotherapy (a condition of partial or complete chemoresistance) may also release pro-metastatic 
EVs that, in turn, facilitate seeding, survival or early colonization of metastatic niches by 
chemoresistant cancer cells. However, it should be cautioned that we did not study mouse survival 
in association with the various treatments, so we currently ignore whether increased metastatic 
seeding and outgrowth in response to chemotherapy-elicited EVs would translate into shorter 
survival in our experimental cancer models.  
 The potential participation of tumour-derived EVs in the process of human breast cancer 
metastasis is currently poorly understood and may be challenging to explore, given the lack of 
validated breast-cancer-specific EV markers 57. In the future, chemotherapy-elicited EVs might 
  
provide biomarkers for predicting metastasis risk associated with neoadjuvant chemotherapy in 
patients who do not achieve a complete response. Interestingly, ANXA6 has been detected in EVs 
isolated from the MDA-MB-231-derived clone 4175, which has lung tropism 20. Furthermore, EV-
associated ANXA6 has been implicated in the progression of pancreatic cancer in a mouse model 42. 
The significance of EV-associated ANXA6 for breast cancer metastasis may, therefore, merit further 
investigation.  
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Figure legends 
 
Figure 1. PTX enhances pulmonary metastasis in mammary tumour-bearing mice 
a. Drug scheduling in tumour-bearing mice. 
b. Cumulative weight of multifocal mammary tumours (mean ± s.e.m.) in MMTV-PyMT mice. 
CREMO, n=14 mice; PTX, n=16. Each dot represents one mouse carrying several tumours. Data 
show two independent experiments combined (EPFL cohort).  
c. Volume of 4T1 or 4T1-mCh tumours (mean ± s.e.m.; n=7 mice/group) in untreated Rag1Ð/Ð mice. 
d. Weight of 4T1-mCh tumours (mean ± s.e.m.) in Rag1−/− mice. CREMO, n=12 mice; PTX, n=14. 
Data show two independent experiments combined.  
e. Weight of 4T1 (n=4) or 4T1-mCh/HER2 tumours (mean ± s.e.m.) in Swiss nu/nu mice. PBS, n=7 
mice; CREMO, n=8; PTX, n=9. Statistical analysis by one-way ANOVA with TukeyÕs multiple 
comparison test.  
f. Representative hematoxylin/eosin (H&E) images of lung sections of MMTV-PyMT mice from the 
experiment shown in (b). Scale bars, 1 mm. Data are quantified in (g) and (h). 
g-i. Number (g) and mean area (h, i) of pulmonary metastases (mean ± s.e.m.) in MMTV-PyMT 
mice. (g, h): CREMO, n=14 mice; PTX, n=16; two independent experiments combined (EPFL 
cohort). (i): PBS, n=21; PTX, n=49; five independent experiments combined (OHSU cohort). 
Statistical analysis in (g) and (i) by unpaired two-tailed StudentÕs t-test. 
j. Fluorescence-activated cell sorting (FACS) analysis of mCh+CD31− cancer cells (mean ± s.e.m.; 
relative to viable CD45− lung-derived cells) in lungs of 4T1-mCh tumour-bearing mice. CREMO, n=8 
mice; PTX, n=9. Statistical analysis as in (g). The FACS panels on the right show the gating 
strategy.  
k. Representative confocal immunofluorescence images showing mCh+ (red) 4T1 cancer cells in 
lung sections of mice from the experiment in (j). Nuclei are stained with DAPI (blue). Scale bars, 200 
µm (left and middle panel) and 50 µm (right panel). 
l. FACS analysis of mCh+CD31− cancer cells (mean ± s.e.m.) in lungs of 4T1 (n=4) or 4T1-
mCh/HER2 tumour-bearing mice. PBS, n=7 mice; CREMO, n=8; PTX, n=9. 
m. FACS analysis of mCh+HER2+CD45− cancer cells (mean ± s.e.m.; absolute cell counts) in blood 
of 4T1-mCh/HER2 tumour-bearing mice. PBS, n=7 mice; CREMO, n=8; PTX, n=9. The FACS 
panels on the right show the gating strategy.  
Source data are shown in Supplementary Table 5. 
 
Figure 2. Chemotherapy-elicited EVs are pro-metastatic in mouse and zebrafish tumour 
model  
a. TEM images of CREMO-EV (n=1 biological sample) and PTX-EV (n=2 independent biological 
samples) isolated from 4T1 cells. One representative image is shown for each EV type. Bottom 
panels show magnified fields of upper panels. Scale bars, 200 nm (upper panels) and 100 nm 
  
(bottom panels). 
b. Schematics illustrating lung pre-conditioning and tumour colonization assays. 
c. Number of 4T1 metastatic nodules (mean ± s.e.m.; n=8 mice/group) in lungs of pre-conditioned 
Balb/c mice. Statistical analysis by unpaired two-tailed StudentÕs t-test. Right panels show 
representative H&E images of lung sections (magnified fields below). Scale bars, 1 mm. 
d. Procedure to isolate tumour-derived EVs from chemotherapy-treated MMTV-PyMT mice. 
e, f. Number of MMTV-PyMT metastatic nodules (mean ± s.e.m.) in lungs of pre-conditioned FVB/n 
mice; CREMO-EV, n=13 mice; PTX-EV, n=14; PBS-EV, n=8; DOX-EV, n=9. Statistical analysis as 
in (c). Lower panels in (e) show representative H&E images of lung sections. Scale bars, 1 mm. 
g. Number of MMTV-PyMT metastatic nodules (mean ± s.e.m.) in lungs of pre-conditioned FVB/n 
mice. PBS, n=9 mice; CREMO 1, n=9; CREMO 10, n=8; PTX 1 mg/kg, n=9; PTX 10 mg/kg, n=9; 
DOX, n=9. CREMO 1 and 10 are the vehicle controls for 1 and 10 mg/kg PTX, respectively. 
Statistical analysis by one-way ANOVA with TukeyÕs multiple comparison test. 
h. Concentration (mean ± s.e.m.; n=5 acquisitions of one sample/condition) and size distribution of 
EVs isolated from plasma of 4T1-mCh tumour-bearing mice treated as indicated, determined by 
NTA.  
i. Schematics illustrating experiments in zebrafish embryos.  
j. Volume of tumour deposits (mean ± s.e.m.) in embryos injected with CREMO-EVs (n=24), PTX-
EVs (n=22), CREMO (n=12) or PTX (n=12), determined by confocal imaging analysis. Statistical 
analysis as in (g).  
k. Confocal image of a representative zebrafish embryo injected with CFP+ MDA-MB-453 cells 
(blue). Blood vessels are GFP+ (green). The right panel shows the caudal haematopoietic area 
(CHA) with CFP+ tumour deposits. Scale bar, 0.5 mm. 
l. Representative confocal images of the CHA of zebrafish embryos, imaged as in (k). Scale bar, 70 
µm. Quantitative data are shown in (j). 
Source data are shown in Supplementary Table 5. 
 
Figure 3. PTX enriches ANXA6 in EVs in a Ca2+-dependent manner 
a. Unsupervised clustering of proteins in CREMO-EV and PTX-EV (n=6 independent EV 
preparations/condition) from 4T1 cells, determined by LC-MS/MS analysis.  
b. LC-MS/MS analysis of CREMO-EV and PTX-EV (n=6 independent EV preparations) showing 
total spectrum count (mean ± s.d.) of ANXA6, CD9 and CD81. Statistical analysis by two-way 
ANOVA with SidakÕs multiple comparison test. 
c. Western blotting analysis of ANXA6, calnexin (CANX), GAPDH and RAB7 in 4T1 cells treated 
with CREMO or PTX for 24h before subcellular fractionation. The ÒmembranesÓ fraction 
encompasses early and late endosomes, endoplasmic reticulum and mitochondria. The experiment 
was performed once. 
d. Western blotting analysis of ANXA6 and CD9 in CREMO- or PTX-treated 4T1 cells, or matched 
  
CREMO-EV or PTX-EV. Additional experiments are shown in Fig. 3e, f, h; Fig. 4c; and 
Supplementary Fig. 1b. 
e. Western blotting analysis of ANXA6 and CD81 in the indicated EV preparations isolated from 
either 4T1 or PyMT-IK1 cells. 
f. Western blotting analysis of the indicated proteins in PyMT-IK1 cells and matched EVs 48h after 
treatment of the cells with PBS, CREMO, PTX, DMSO or DOX, with or without the calcium chelator 
BAPTA-AM. One representative experiment is shown of three performed for EVs and one for cells. 
g. ANXA6 band intensity (mean ± s.d.; n=3 independent experiments, one of which is shown in (f) 
above) in the indicated EV preparations analysed by Western blotting. Statistical analysis as in (b). 
h. Western blotting analysis of EVs from 4T1 cells treated for 48h with PBS, CREMO or PTX, with or 
without BAPTA-AM. One representative experiment is shown of three performed. 
i. ANXA6 band intensity (normalized to CD81; mean ± s.d.; n=3 independent experiments, one of 
which is shown in (h) above) in the indicated EV preparations. Statistical analysis as in (b). 
j. Protein content by BCA (left panel) and concentration by NTA (right panel) of the indicated EVs 
(mean ± s.d.; n=3 independent EV preparation/condition) obtained from 4T1 cells treated with or 
without BAPTA-AM. Statistical analysis as in (b). 
Source data are shown in Supplementary Table 5. Unprocessed blots are shown in 
Supplementary Fig. 9. 
 
Figure 4. EV-associated ANXA6 promotes mammary tumour metastasis 
a. Schematics of the lentiviral vectors used to disrupt the expression of Anxa6, Rab27a or Rela in 
cells. 
b, c. Western blotting analysis of ANXA6, GAPDH and CD81 in 4T1-mCh cells (b) or secreted EVs 
(c). Anxa6-WT (parental line) and two independent Anxa6-KO clones are shown, either untreated (b) 
or treated as indicated (c). The experiments were performed once. 
d. mCh mean fluorescence intensity (MFI; left y axis) and concentration by NTA (right y axis) of EVs 
(mean ± s.d.; n=3 independent cell cultures/condition) released by Anxa6-KO 4T1-mCh cells (clone 
#1) treated for 72h with CREMO or PTX. Statistical analysis by unpaired two-tailed StudentÕs t-test. 
e. Representative wide-field TEM images of the indicated EVs isolated from Anxa6-WT (top panels) 
or Anxa6-KO (clone #1, bottom panels) 4T1-mCh cells. Scale bars, 200 nm. The experiment was 
performed once. 
f. Mode size (mean values ± s.d.) of the indicated EVs isolated from Anxa6-WT (top panel) or 
Anxa6-KO (clone #1, bottom panel) 4T1-mCh cells, determined by NTA. Data show results from n=5 
(Anxa6-WT) and n=3 (Anxa6-KO) independent EV preparations. 
g. Concentration (mean ± s.e.m.; n=3 acquisitions of one sample/condition) and size distribution of 
EVs isolated from medium conditioned by CREMO- or PTX-treated Anxa6-KO 4T1-mCh cells (clone 
#1), determined by NTA.  
h. mCh+ metastatic area fraction per lung section (mean ± s.e.m.) in Rag1-/- mice pre-conditioned 
  
with the indicated EVs. CREMO-EV/Anxa6-WT, n=7 mice; PTX-EV/Anxa6-WT, n=7; CREMO-
EV/Anxa6-KO (clone #1), n=7; PTX-EV/Anxa6-KO (clone #1), n=7. Statistical analysis by two-way 
ANOVA with TukeyÕs multiple comparison test. Representative images of lung sections stained with 
DAPI (white) are shown on the right; the mCh signal (red) was acquired as direct fluorescence. 
Scale bars, 1 mm. 
i. mCh+ metastatic area fraction per lung section (mean ± s.e.m.) in Rag1-/- mice pre-conditioned 
with EVs. DMSO-EV/Anxa6-WT, n=7 mice; DOX-EV/Anxa6-WT, n=8; DMSO-EV/Anxa6-KO (clone 
#1), n=8; DOX-EV/Anxa6-KO (clone #1), n=8. Statistical analysis as in (h). 
Source data are shown in Supplementary Table 5. Unprocessed blots are shown in 
Supplementary Fig. 9. 
 
Figure 5. PTX induces CCL2 expression and Ly6C+ monocyte expansion in lungs of 
mammary tumour-bearing mice 
a. Quantitative polymerase chain reaction (qPCR) analysis of the indicated genes (mean ± s.e.m.) in 
lungs of either tumour-free (TF) or 4T1 tumour-bearing (TB) mice treated as indicated. TF + 
CREMO, n=5 mice; TF + PTX, n=5; TB + CREMO, n=8; TB + PTX, n=9. Statistical analysis by two-
way ANOVA with TukeyÕs multiple comparison test. 
b. ELISA-based CCL2 protein (mean ± s.e.m.) in lungs of mice treated as in (a). Tumour-free + 
CREMO, n=5 mice; Tumour-free + PTX, n=5; Tumour-bearing + CREMO, n=6; Tumour-bearing + 
PTX, n=6. Statistical analysis as in (a).  
c. FACS analysis of CD45+CD11b+Ly6C+Ly6GÐF4/80+ monocytes (Ly6C+ Mo) in lungs of tumour-
bearing mice. A representative sample is shown to illustrate the gating strategy. FMO, fluorescence 
minus one. 
d-g. FACS analysis of Ly6C+ Mo (mean ± s.e.m.) in tumour-bearing mice treated as indicated. Data 
show the frequency of Ly6C+ monocytes in the CD45+ population, relative to control (CREMO or 
PBS). (d): CREMO, n=7 mice; PTX, n=8. (e): PBS, n=5; CREMO, n=5; PTX, n=5. (f): PBS, n=7; 
CREMO, n=8; PTX, n=9. (g): CREMO, n=13; PTX, n=14. Statistical analysis by unpaired two-tailed 
StudentÕs t-test (d, g) or one-way ANOVA with TukeyÕs multiple comparison test (e, f). Data in (g) 
show three independent experiments combined. 
h, i. FACS analysis of Ly6C+ Mo (mean ± s.e.m.) in lungs of tumour-free FVB/n (h) or Rag1-/- (i) mice 
treated as indicated and analysed two days after treatment. (h): PBS, n=12 mice; CREMO, n=6; 
PTX 1 mg/kg, n=8; PTX 10 mg/kg, n=6; DOX, n=6. (i): CREMO, n=5; PTX, n=5. Statistical analysis 
by one-way ANOVA with TukeyÕs multiple comparison test (h) or unpaired two-tailed StudentÕs t-test 
(i). 
Source data are shown in Supplementary Table 5. 
 
Figure 6. Ly6C+ monocytes mediate the pro-metastatic activity of chemotherapy-elicited EVs  
a. Schematics of EV pre-conditioning studies in tumour-free mice. 
  
b-d. qPCR analysis of Ccl2 (mean ± s.e.m.) in lungs of tumour-free mice that received EVs. (b): 
CREMO-EV, n=8; PTX-EV, n=9. (c): CREMO-EV, n=8; PTX-EV, n=7. (d): CREMO-EV, n=10; PTX-
EV, n=9. Statistical analysis by unpaired two-tailed StudentÕs t-test. 
e-g. FACS analysis of Ly6C+ Mo (mean ± s.e.m.) in lungs of tumour-free mice that received EVs. 
(e): CREMO-EV, n=8; PTX-EV, n=9. (f): CREMO-EV, n=6; PTX-EV, n=7. (g): PBS (no EVs), n=11; 
CREMO-EV, n=14; PTX-EV, n=15. Statistical analysis by unpaired two-tailed StudentÕs t-test (e, f) or 
one-way ANOVA with TukeyÕs multiple comparison test (g). 
h. qPCR analysis of Ccr2 (mean ± s.e.m.) in lungs of mice that received MMTV-PyMT tumour-
derived CREMO-EV (n=10) or PTX-EV (n=9). Statistical analysis as in (b).  
i. Correlation between Ccl2 and Ccr2 transcript levels in lungs of FVB/n mice shown in (d) and (h). 
The Pearson correlation coefficient (r) is indicated.  
j, k. qPCR analysis of Ccl2 (j) and FACS analysis of Ly6C+ Mo (k) in the lungs of tumour-free mice 
(mean ± s.e.m.) that received PBS-EV (n=5) or DOX-EV (n=5). Statistical analysis as in (b). 
l. Bioluminescence (BL) analysis (total photon flux; mean ± s.e.m.) of Ccr2 WT or KO mice pre-
conditioned with EVs, analysed at day 10 post-cell injection. The right panel shows representative 
mice. CREMO-EV/Ccr2-WT, n=10; PTX-EV/Ccr2-WT, n=11; CREMO-EV/Ccr2-KO, n=7; PTX-
EV/Ccr2-KO, n=8. Statistical analysis by two-way ANOVA with TukeyÕs multiple comparison test. 
Data show three independent experiments combined. 
m. qPCR analysis of Ccr2 (mean ± s.e.m.) in myeloid cells (Ly6C+ Mo; Ly6Clow Mo; and non-alveolar 
macrophages, Mac) FACS-sorted from lungs of tumour-free mice that received MMTV-PyMT 
tumour-derived CREMO-EV (n=5; except for Mac, n=4) or PTX-EV (n=6). Statistical analysis as in 
(l). 
n, o. qPCR analysis of Ccl2 and Ccr2 (n) and FACS analysis of Ly6C+ Mo (o) in lungs of mice 
(mean ± s.e.m; n=6 mice) that received CREMO-EV or PTX-EV from either Anxa6-WT or Anxa6-KO 
4T1-mCh cells. Statistical analysis by two-way ANOVA with SidakÕs multiple comparison test. 
Source data are shown in Supplementary Table 5. 
 
Figure 7. Chemotherapy-elicited EVs promote inflammatory EC activation through ANXA6 
transfer 
a. FACS of mCh+ ECs (mean ± s.e.m.) in lungs of 4T1 (n=6) or 4T1-mCh (CREMO, n=8; PTX, n=9) 
tumour-bearing Rag1Ð/Ð mice. Statistical analysis by one-way ANOVA with TukeyÕs multiple 
comparison test. Right panels show gating strategy. 
b. Representative confocal images of anti-CD31 endothelial (green) and anti-mCh (magenta) 
immunostaining of lung sections from 4T1-mCh tumour-bearing mice treated as in (a); nuclei are 
stained with DAPI (blue). Scale bars, 10 µm.  
c. FACS of mCh+ ECs (mean ± s.e.m.) in lungs of 4T1 (n=4) or 4T1-mCh/HER2 (PBS, n=7; 
CREMO, n=8; PTX, n=9) tumour-bearing Swiss nu/nu mice. Statistical analysis as in (a). 
d. Western blotting analysis of the indicated proteins in Anxa6-KO bEnd.3 cells. The experiment was 
  
performed twice; Supplementary Fig. 6b shows a replicate experiment. 
e. Duolink staining of Anxa6-KO bEnd.3 cells showing ANXA6/p65 proximity (number of white 
dots/cell; mean ± s.e.m.; n=8 randomly selected images, each containing at least 12 cells). 
Statistical analysis as in (a). Right panels show representative images; nuclei are stained with DAPI 
(blue). Scale bars, 30 µm. Data show one experiment of two performed. 
f. Western blotting analysis of p65 (left), NF-kB activity (middle), and qPCR of Ccl2 (right) in bEnd.3 
cells (mean ± s.d.; n=3 independent cell cultures/condition). Statistical analysis by unpaired two-
tailed StudentÕs t-test. 
g, h. NF-kB activity (g) and qPCR of Ccl2 (h) in bEnd.3 cells (mean ± s.d.; n=3 independent cell 
cultures/condition). Statistical analysis by two-way ANOVA with SidakÕs multiple comparison test. 
Data show one experiment of two (g) or three (h) performed. 
i, j. qPCR analysis of Ccl2 (i) and NF-kB activity (j) in bEnd.3 cells (mean ± s.d.; n=3 independent 
cell cultures/condition). Statistical analysis by two-way ANOVA with TukeyÕs multiple comparison 
test (i, left panel) or unpaired two-tailed StudentÕs t-test (i, right panel; and j). 
k. qPCR of Ccl2 in mCh+CD31+CD45Ð ECs sorted from lungs of FVB/n mice (mean ± s.e.m.; n=5 
mice). Statistical analysis by unpaired one-tailed StudentÕs t-test. Right panel shows the purity of the 
sorted ECs. 
Source data are shown in Supplementary Table 5. Unprocessed blots are shown in 
Supplementary Fig. 9. 
 
Figure 8. ANXA6 is detected in circulating EVs of breast cancer patients undergoing 
neoadjuvant chemotherapy 
a. Western blotting analysis of EVs isolated from MDA-MB-231 cells treated as indicated. The 
experiment was performed three times for PTX and once for DOX. 
b. Schematic of the treatment timeline and time-points of blood collection in breast cancer patients 
(n=6). AC, anthracycline (DOX) plus cyclophosphamide.  
c. LC-MS/MS-based quantification of ANXA6 in EVs isolated from plasma of breast cancer patients 
(n=6) before chemotherapy (pre-treatment), after AC, and after PTX. The data show quantitative 
values of ANXA6 presented as fold-change versus pre-treatment level. Note that the amount of EVs 
that could be isolated from patient #38 after PTX was insufficient to perform LC-MS/MS analysis. 
Tumour response was assessed at the time of surgery. 
d. Western blotting analysis of ANXA6 in plasma EVs of one patient (#56), analysed at the indicated 
time-points. The experiment was performed once. 
Source data are shown in Supplementary Table 5. Unprocessed blots are shown in 
Supplementary Fig. 9. 
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Online Methods 
 
Mice 
FVB/n, Balb/c, C57BL/6 and Swiss nu/nu mice were purchased from Charles River Laboratories. Ccr2-KO 
mice (C57BL/6 background) were obtained from The Jackson Laboratory (https://www.jax.org) and bred 
under standard conditions at the University of Edinburgh (United Kingdom). Rag1
Ð/Ð
 mice (C57BL/6 
background) were available in the EPFL mouse facility (Switzerland). Transgenic MMTV-PyMT mice (FVB/n 
background) were available in both EPFL mouse facility and Department of Comparative Medicine barrier 
facility (Oregon). Male mice heterozygous for the Polyoma virus middle TAg (PyMT) were bred with wild-
type females; pups were genotyped by Transnetyx (http://www.transnetyx.com). All mice employed in this 
study were maintained in pathogen-free barrier animal facilities in accord with State regulations for the care 
and use of mice in experimental research.  
 The studies involving mice were compliant with all relevant ethical regulations regarding animal 
research. Most of the experiments were performed at EPFL; some experiments were performed at the 
University of Edinburgh (Ccr2-KO mice) and at Oregon Health & Science University (OHSU), Portland 
(MMTV-PyMT mice, partim). All procedures were performed according to protocols approved by the 
Veterinary Authorities of the Canton Vaud according to the Swiss Law (licenses 2577, 2577.1 and 2916); the 
UK Animal Scientific Procedures Act (1986) license (PPL 70/8065); and the Public Health Service of USA 
(PHS), the Office for the Protection from Research Risks (OPRR) A-3304-01, the United States Department 
of Agriculture (USDA) 92-R-001, and the Association for Assessment and Accreditation of Laboratory 
Animal Care (AAALAC) International. OHSU maintains AAALAC International accreditation and OLAW 
assurance (A3304-01), and all procedures with small animals at OHSU were IACUC approved 
(IS00001484).  
 
Cell lines 
The mouse cell lines 4T1 (mammary adenocarcinoma; from ATCC), bEnd.3 (brain endothelial cells; 
provided by F. Bussolino, University of Turin, Italy), 293T (provided by L. Naldini, San Raffaele Scientific 
Institute, Milan, Italy), and PyMT-IK1 (mammary adenocarcinoma; isolated in the De PalmaÕs lab) were 
maintained in Iscove's modified Dulbecco's medium (IMDM, Sigma) supplemented with 10% fetal bovine 
serum (FBS; Gibco), L-glutamine (Amimed) and penicillin/streptomycin (Gibco). The PyMT-IK1 cell line was 
isolated from a primary mammary tumour of a 14-week old, transgenic MMTV-PyMT female mouse. Mouse 
E0771-LG cells (mammary adenocarcinoma; derived from the parental cell line E0771), either unmodified or 
stably transfected with a firefly luciferase cDNA for in vivo bioluminescence imaging (E0771-LG:Fl; both 
provided by T. Kitamura, University of Edinburgh, United Kingdom) 
49,58
, were maintained in DulbeccoÕs 
medium (DMEM, Gibco) with 10% FBS, L-glutamine and penicillin/streptomycin. The human cell line MDA-
MB-231 (breast adenocarcinoma; from ATCC) was cultured in RPMI 1640 (Gibco) with 10% FBS and 
penicillin/streptomycin. The human melanoma cell line MDA-MB-435 stably transfected to express cyan 
fluorescent protein (CFP; provided by R. Klemke, University of Sheffield, United Kingdom) was maintained in 
DMEM with 10% fetal calf serum (FCS; BioWhittaker, United Kingdom) and 50 µg/ml G418 (Sigma) to 
maintain CFP expression. All cell lines used tested negative for Mycoplasma contamination. 
 Primary cell cultures 
Bone marrow dendritic cells (BMDCs) were obtained by flushing long bones of 6-week old C57BL/6 mice, as 
described previously 
29
, and cultured for 6 days in RPMI 1640 medium with 10% FBS, L-glutamine, 
penicillin/streptomycin, and GM-CSF (100 ng/ml, Peprotech).  
 Mouse embryonic fibroblasts (MEFs) were obtained from C57BL/6 mice on day E14.5, as described 
previously 
59
, and cultured in DMEM with 10% FBS, L-glutamine, penicillin/streptomycin. We verified the 
purity of MEFs (CD45
Ð
CD31
Ð
EpCAM
Ð
CD140a
+
) by fluorescence-activated cell sorting (FACS).  
  In order to obtain MMTV-PyMT tumour-derived cells, primary mammary tumours of 14-week old female 
MMTV-PyMT mice were dissected, minced and digested with collagenase IV (0.2 mg/ml, Worthington), 
dispase (2 mg/ml, Life Technologies) and DNaseI (0.002 mg/ml, Life Technologies) in IMDM medium for 30 
min at 37¡C. The cell suspensions were filtered using a cell strainer (70 µm) before plating. Tumour-derived 
cells were then cultured for 48h in IMDM supplemented with 5% EV-depleted FBS, L-glutamine, and 
penicillin/streptomycin before intraveneous injection in tumour-free mice. 
 Treatment of primary cells with chemotherapeutic drugs was conducted in complete medium 
supplemented with EV-depleted, 5% FBS for 3 days. At the end of the treatment, the viability of BMDCs and 
MEFs was assessed by Trypan Blue staining and WST-1 assay, respectively. 
   
Generation, production and use of lentiviral vectors (LVs) 
Lentiviral vectors (LVs) expressing a CD9.mCherry fusion protein or human HER2 were described 
previously 
29,60
. In order to disrupt Rab27a, Rela or Anxa6 in bEnd.3 or 4T1 cells, we generated self-
inducible CRISPR-Cas9-based LVs, as described previously 
29
. Briefly, we annealed and ligated the DNA 
sequences shown below using the BsmBI restriction site in the U6-(sgRNA).TetO-CAS9.hPGK-
PURO/2A/rtTA LV (Ref 29): 
Rab27a sense: ACCGTATCCAGTTTCGGACATTG 
Rab27a antisense: AAACCAATGTCCGAAACTGGATA 
Rela sense: ACCGGGCTGGGGTCGGCGTACGG 
Rela antisense: AAACCCGTACGCCGACCCCAGCC 
Anxa6 sense: ACCGGATTCCAGGTCTCGCTCAT 
Anxa6 antisense: AAACATGAGCGAGACCTGGAATC. 
 To generate the NF-kB reporter LV, we isolated the minimal mouse Fos promoter element and three 
copies of the major histocompatibility complex (MHC) class I KB element (TGGGGATTCCCCA) by digesting 
a plasmid obtained from Addgene (https://www.addgene.org/26699/) with HincII and PvuII restriction 
enzymes. The sequence was then inserted downstream to the minimal CMV promoter (mCMV) of a 
bidirectional hPGK.GFP/mCMV.mCh LV, after digestion with EcoRV.  
 Vesicular stomatitis virus (VSV)-pseudotyped, third-generation LVs were produced by transient four-
plasmid co-transfection into 293T cells and concentrated by ultracentrifugation, as described previously 
61
. 
Expression titres of LVs encoding fluorescent proteins were determined in 293T cells by limiting dilution. LV 
stocks were stored at Ð80¡C.  
 PyMT-IK1 and 4T1 cells were transduced with LVs expressing CD9.mCh; 4T1-mCh cells were further 
transduced with a HER2-expressing LV for use in some experiments. Cells expressing HER2 and/or mCh 
were sorted by FACS (Aria II apparatus, BD Biosciences) to establish pure cell populations expressing the 
transgene(s) of interest. 
 bEnd.3 and 4T1-mCh cells were transduced with CRISPR-Cas9 LVs to disrupt Rab27a, Rela or Anxa6. 
After transduction, the cells were cultured in complete IMDM medium with puromycin (5-10 µg/ml, Sigma) 
and doxycycline (10 µg/ml, Sigma) for 4 days to select transduced cells. The cells were then plated in 
normal medium to isolate cell clones. Cell colonies showing no expression of RAB27A, RELA or ANXA6 by 
Western blotting were expanded and employed in further experiments. 
 
Cytotoxic drugs 
Paclitaxel (PTX) dissolved in cremophor EL (Labatec) was obtained at stock concentration of 6 mg/ml. PTX 
was used at 100 ng/ml (cell culture experiments), 10 mg/kg (mouse models) or 100 nM (zebrafish models), 
unless indicated otherwise. Cremophor EL (CREMO; Sigma) was used as control vehicle for PTX, both in 
vitro and in vivo. Oregon Green-488-conjugated PTX (Thermo Fisher Scientific) was reconstituted in DMSO 
and used at a concentration of 100 ng/ml. Doxorubicin and docetaxel (Sigma) were reconstituted in DMSO, 
while gemcitabine (Sigma) was reconstituted in water. Unless indicated otherwise, doxorubicin, docetaxel 
and gemcitabine were used in cell culture experiments at 200, 100 and 10 ng/ml, respectively. For mouse 
studies, doxorubicin (DOX; adriblastine; Pfizer) was dissolved in PBS and used at 8 mg/kg. 
 Cytotoxic drugs (or control vehicle) were added once to the cell culture medium and the experiments 
terminated after 24 to 72h. Mice received three doses of either PTX or DOX, as described below.   
 
Treatment of transgenic MMTV-PyMT mice 
Female transgenic mice were treated with 10 mg/kg PTX or CREMO in PBS intraperitoneally (EPFL cohort) 
or intraveneously (OHSU cohort), or 8 mg/kg DOX or PBS intraperitoneally. All mice received 3 drug/vehicle 
doses at 5-day (PTX) or 7-day (DOX) intervals, starting at 11-12 weeks of age, when multifocal mammary 
tumours are evident in this model 
46
. The mice were euthanized 3 days after the last dose. Tumour weight 
measurements were performed at necropsy by dissecting the ten mammary glands. 
 
Treatment of mice carrying subcutaneous tumours 
Subcutaneous 4T1 tumours were established by implanting 10
6
 4T1, 4T1-mCh or 4T1-mCh/HER2 cells in 
the right flank of 6 to 8-week old Balb/c, Rag1
−/−
 or Swiss nu/nu mice. Both female and male Rag1
−/−
 mice 
were employed; only female Balb/c and Swiss nu/nu mice were employed. Treatments were initiated when 
the tumour volume reached 100-200 mm
3
; the mice were euthanized 3 days after the last drug dose. 
Tumour growth was monitored biweekly and the tumour size determined by caliper measurements. The 
tumour volume was calculated using the formula: tumour volume [mm
3
] = (length [mm]) × (width [mm]) × 
(height [mm]) × 0.5236. Tumour weight measurements were performed at necropsy.  
 
Isolation of EVs from media conditioned by continuous and primary cell cultures 
In order to isolate EVs, cells were cultured and expanded in the appropriate medium. Cells at about 40-50% 
confluence were then moved to medium containing 5% EV-depleted FBS obtained by ultracentrifugation of 
standard FBS at 134000 x g for 16h at 4¡C, followed by filtering through a 0.1 µm vacuum filtration bottle. 
EVs were isolated from the conditioned medium using sequential ultracentrifugation, as described 
29,30
. 
Briefly, conditioned medium was centrifuged at 500 x g for 5 min; 2000 x g for 10 min; and 4600 x g for 20 
min, at 4¡C to remove dead cells and debris. The medium was then ultracentrifuged at 134000 x g for 70 
min at 4¡C using a Beckman ultracentrifuge and SW32Ti rotor. The pellet was washed in 35 ml of PBS and 
ultracentrifuged again at 134000 x g for 70 min at 4¡C. The resulting EV preparation was dissolved in PBS 
or RIPA buffer (Sigma), depending on the application, and either used immediately or stored at −80¡C. The 
average EV yield obtained from 4T1, PyMT-IK1, MDA-MD-231, E0771-LG, BMDCs and MEFs was, 
respectively, 7.3, 0.8, 0.8, 1.8, 0.1 and 1 µg of EVs (determined by BCA) per ml of cell culture medium. 
 
Isolation of MMTV-PyMT tumour-derived EVs 
After treatment of the mice with cytotoxic drugs, primary MMTV-PyMT tumours were made into single cell 
suspensions as described above. The tumour-derived cells were cultured for 48h in IMDM supplemented 
with 5% EV-depleted FBS, L-glutamine and penicillin/streptomycin before EV isolation by ultracentrifugation. 
The average yield of purified EVs was 50 µg per gram of tumour. 
 
Isolation of EVs from mouse or human plasma 
We obtained blood of 4T1-mCh tumour-bearing mice treated with PTX or CREMO by cardiac puncture after 
deep sedation (150 mg/kg pentobarbital, intraperitoneally). To obtain plasma for EV isolation or mCh 
quantification, blood was centrifuged at 500 x g for 5 min; 2000 x g for 15 min; and 10000 x g for 20 min at 
4¡C to remove cells, debris and large vesicles. Human plasma was obtained as described below.  
 To isolate EVs, plasma was ultracentrifuged at 134000 x g for 70 min at 4¡C using a Beckman 
ultracentrifuge and SW55Ti rotor. The pellet was washed in 4.5 ml of PBS and ultracentrifuged again at 
134000 x g for 70 min at 4¡C. The resulting EV preparation was dissolved in PBS and either used 
immediately or stored at −80¡C. 
 
Quantification of EVs 
EV preparations were analysed for protein content using the BCA Protein Assay Reagent Kit (Thermo Fisher 
Scientific).  
 The size and concentration of EVs were determined by Nanoparticle Tracking Analysis (NTA) using a 
Nanosight NS300 device (Malvern Instruments, United Kingdom). We tested different sample dilutions (1:50 
to 1:2000, in PBS) whereby particle concentration was within the optimal range of detection (5 × 10
7
 - 1 × 10
9
 
particles/ml). All camera settings were set at the beginning of the session and kept fixed during all 
acquisitions in a given experiment: camera level, 7-9; camera gain, 10-12; detection threshold, 2-4. For each 
sample, at least three videos of 60 sec for at least one EV dilution were taken and analysed using the NTA 
software 3.0 with default settings. 
 
Transmission electron microscopy (TEM) of purified EVs 
Purified EVs (5 µg in 15 µl of PBS) were applied to carbon-coated 400 mesh grids (Electron Microscopy 
Sciences) for 5 min, then washed with PBS and stained with 2% uranyl acetate for 30 sec, as described 
previously 
62
. Images were obtained using a transmission electron microscope device (Tecnai Spirit, FEI 
Company).  
 
Sucrose gradient fractionation of EVs 
Purified EVs were subjected to continuous sucrose gradient fractionation using established procedures 
31,63
. 
Briefly, twelve stock solutions with decreasing sucrose concentration were layered on top of purified EVs 
(800 µg, in 100 µl PBS) in a total volume of 12 ml, followed by ultracentrifugation at 100000 x g for 16h at 
4¡C with a Beckman ultracentrifuge and a SW40Ti rotor. Six fractions of 2 ml each were then collected and 
transferred to new tubes; the density of each sucrose fraction was measured using a refractometer. Each 
fraction was washed with 10 ml of PBS and ultracentrifuged at 110000 x g for 70 min at 4¡C as above. EVs 
were resuspended in 100 µl of PBS prior to subsequent analyses.  
 
Quantification of EV-associated mCh fluorescence in cell culture media and mouse plasma 
mCh fluorescence was measured in 100 µl of PBS containing purified EVs, or 100 µl of mouse plasma, 
using a spectrophotometer (TECAN infinite2000 plate-reader, TECAN). The following parameters were 
used: excitation wavelength, 586 nm; emission wavelength, 625 nm; number of reads, 4.  
 To degrade free (non-EV-associated) mCh protein, a proteinase K reaction was performed using 40% 
of plasma and 0.25 mg/ml proteinase K (Promega) in 1 mM guanidinium hydroxide (GuOH)/30mM Tris/5mM 
CaCl2, for 2h at 55
o
C. 
 
Determination of PTX and DOX concentration in EVs 
The content of PTX and DOX in purified EVs was assessed by measuring the fluorescence intensity of 
Oregon Green-488-conjugated PTX (Thermo Fisher Scientific) and the spontaneous fluorescence of DOX 
(Sigma), respectively, using a spectrophotometer (TECAN infinite2000 plate-reader). We measured several 
dilutions of the EVs in PBS, as well as equal amounts of drug-free EVs from DMSO-treated cells for 
background subtraction. The following parameters were utilized for measuring fluorescence of Oregon 
Green-488-conjugated PTX and DOX, respectively: excitation wavelengths, 495 and 470 nm; emission 
wavelengths, 525 and 585 nm; number of reads: 4 per EV dilution. Standard curves of Oregon Green-488-
PTX and DOX were employed to extrapolate drug concentration in EVs from fluorescence intensity values. 
 
EV pre-conditioning of mice 
Cell- or tumour-derived EVs (15 µg in 100 µl of PBS) were centrifugated at 4600 x g for 1 min at 4
o
C to 
remove sedimentable aggregates before intravenous injection into 6 to 8-week old, tumour-free mice 
(FVB/N, C57BL/6/Rag1
-/-
, Balb/c, C57BL/6/Ccr2-KO or C57BL/6). Two EV doses were administered two 
days apart. For gene expression and FACS analyses, tumour-free mice were euthanized 2 days after the 
last EV dose. For experimental metastasis (lung colonization) studies, cancer cells were infused 
intravenously one day after the last EV administration and euthanized at the time points described below.  
  
Lung colonization studies 
4T1-mCh cells (5 x 10
5
) were injected intravenously in 6-8 week-old, male or female Rag1
-/-
 mice one day 
after EV pre-conditioning. The mice were euthanized 3 weeks after cancer cell injection and lungs fixed, 
sectioned, and analysed for direct mCh fluorescence to quantify metastatic tumour burden.  
 4T1 cells (1 x 10
5
) were injected intravenously in 6 week-old female Balb/c mice one day after EV pre-
conditioning. The mice were euthanized 10 days after cancer cell injection and lungs fixed, sectioned, and 
stained with hematoxylin/eosin (H&E) to quantify metastatic tumour burden. 
 MMTV-PyMT tumour-derived cells (5 x 10
5
) were injected intravenously into 6-7 week-old female FVB/n 
mice one day after EV pre-conditioning. The mice were euthanized three weeks after tumour cell injection 
and lungs fixed, sectioned, and stained with H&E to quantify metastatic tumour burden. 
 E0771-LG:Fl cells (1x10
6
) were intravenously injected into 6-8 week-old, male or female C57BL/6 or 
C57BL/6/Ccr2-KO mice one day after EV pre-conditioning. Bioluminescence was determined 10 days after 
cancer cell injection.   
 
In vivo bioluminescence imaging 
C57BL/6 or Ccr2-KO mice were anesthetised with isofluorane (3-4 % induction, 1-2% maintenance) and 
administered 150 µg of luciferin (GoldBio) intraperitoneally per gram of body weight. Mice were imaged 
under Photon Imager Optima (Biospace Lab) for 15 min until the bioluminescence signal reached a plateau. 
Imaging was done 30 min and 10 days after E0771-LG:Fl cell injection. Photon counts 
(photon/second/cm2/sr) in the lung area were analysed using the M3 Vision software (Biospace Lab).  
 
Analysis of pulmonary metastasis in mice 
To analyse lungs for the presence of mCh-negative tumour nodules, formalin or paraformaldehyde-fixed 
lungs were sectioned into 5- or 8 µm-thick sections, respectively, at 100 µm intervals. Three to four large 
lung sections were stained with H&E. Sections were scanned with an Olympus slide scanner (VS120-L100) 
endowed with a 10x objective and fully automated scanning capabilities. Tumour nodules (>10-20 cancer 
cells) were counted and their area measured using the OlyVIA (Olympus) and ImageJ softwares, 
respectively. The number and mean area of the metastatic nodules were calculated by averaging data from 
individual sections. 
 To analyse lungs for the presence of mCh
+
 tumour nodules or disseminated cancer cells, 
paraformaldehyde-fixed lungs were sectioned into 8 µm-thick sections at 100 µm intervals. Four large 
sections were counterstained with DAPI and scanned with an Olympus slide scanner (VS120-L100) to 
acquire both mCh and DAPI fluorescence. Images were analysed using the ImageJ software and the VSI 
Biop tool. The total metastatic area was calculated by normalizing the mCh
+
 area to the total lung (DAPI
+
) 
area and by averaging data from individual sections. In some experiments, mCh
+ 
cancer cells were also 
quantified by FACS analysis of homogenised lung tissue. 
  
Zebrafish studies  
The studies involving zebrafish (Danio rerio) were compliant with all relevant ethical regulations regarding 
animal research. Zebrafish were maintained according to standard protocols. All tumour studies were 
authorised by the UK Home Office under licence 40/3690 and performed at the zebrafish facility of the 
University of Sheffield, United Kingdom. The transgenic zebrafish line fms:UNM 
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 was crossed with the 
Tg(tie2:GFP) line 
65
 to obtain the double transgenic fms:UNM; Tg(tie2:GFP) line, which enables the direct 
visualization of blood and lymphatic vessels. 
 Zebrafish embryos were maintained in E3 medium at 28¡C. Before injection of EVs (or free drug) and 
cancer cells, 56h post-fertilization embryos were anesthetized by immersion in 0.04 mg/ml of tricaine 
(MS222; Sigma) and immobilized in 1% low melting point agarose (Sigma). Each embryo received 200-300 
CFP
+
 MDA-MB-435 cells together with purified EVs (0.326 µg/ml) or drugs (PTX or CREMO; 100 µM) in 4 nl 
of saline, via the duct of Cuvier with a microinjector (World Precision Instruments, United Kingdom). 
 The embryos were analysed 18 h post-injection. After anaesthesia/immobilization, we used a spinning 
disc confocal microscope (Olympus IX81, PerkinElmer, UK) to image the tail of the zebrafish and capture Z-
stacks at 3 µm increments. The full tail of the embryo was covered by two images at 10x magnification. 
Image acquisition and processing were performed with Volocity 6.3 software (Improvision, Coventry, United 
Kingdom). Cancer cell aggregates were visualized by capturing the CFP fluorescence of the cells, and the 
total metastatic volume was calculated from the XYZ analysis of CFP fluorescence in each of the tumour Z-
stacks. 
 
Preparation of tumours, lungs and livers for FACS analysis and cell sorting  
Before sacrifice, deeply anaesthetised mice were perfused with PBS to remove intravascular blood cells. 
Tumours, lungs and livers were then harvested, washed extensively in PBS, and then minced before 
digestion with collagenase IV (0.2 mg/ml), dispase (2 mg/ml) and DNase I (0.002 mg/ml) in IMDM medium 
for 20 min at 37¡C. The cell suspensions were filtered using a cell strainer (70 µm) and washed in PBS 
containing 2 mM EDTA and 2% FBS. Red blood cells were lysed using a Red blood cell Lysis buffer 
(Sigma). 
 Cell suspensions were incubated with rat anti-mouse FcγIII/II receptor (CD16/CD32) blocking 
antibodies (4 µg/ml) for 15 min at 4¡C prior to extracellular staining with conjugated antibodies 
(Supplementary Table 4) for 20 min at 4¡C. Before analysis, cells were resuspended in DAPI-containing 
buffer to identify non-viable cells. All samples were analysed using an LSRII apparatus (BD Biosciences). 
Compensation was performed using fluorescence-minus-one (FMO) controls. 
 To sort cells, we used a FACS Aria II apparatus (BD Biosciences). Each cell population was isolated 
from a single organ/mouse. Typically, 2x10
3
 to 2x10
5
 cells were obtained from each sorting session and all 
populations were verified by performing post-sorting analysis. Cell types were identified using the following 
combinations of cell markers:  
Endothelial cells (ECs): CD45
−
CD31
+
  
Ly6C
+ 
classical monocytes: CD45
+
CD11b
+
Ly6C
+
Ly6G
−
F4/80
+
  
Ly6C
low 
monocytes: CD45
+
CD11b
+
Ly6C
low
Ly6G
−
F4/80
−
 
Monocytes/macrophages: CD45
+
CD11b
+
Gr1
−
 or CD45
+
CD11b
+
Ly6G
−
Ly6C
low
 
Alveolar lung macrophages: CD45
+
CD11c
+
SiglecF
+
F4/80
+
   
Non-alveolar lung macrophages: CD45
+
CD11c
−
SiglecF
−
CD11b
+
Ly6G
−
Ly6C
low
F4/80
+
  
Neutrophils: CD45
+
CD11b
+
Ly6G
+
 
Disseminated cancer cells: CD45
−
CD31
−
mCh
+
 
 
Quantification of circulating cancer cells by FACS  
Blood was collected by cardiac puncture of deeply anesthetised mice and collected in EDTA-containing 
tubes. To enumerate circulating cancer cells, we used 250 µl of erythrocyte-depleted blood. The cell 
suspension was processed as described above, and circulating cancer cells identified as CD45
−
mCh
+
HER2
+
 
cells using an LSRII apparatus.  
 
Immunofluorescence staining of tumour and organ sections 
Tumours and organs were fixed in 4% paraformaldehyde for 24h at 4
o
C, equilibrated in sucrose solutions for 
24h, and then embedded in O.C.T compound (Cryomatrix, Thermo Fisher Scientific) on dry ice with iso-
pentane (VWR Chemicals) before storage at -80¡C. Tissue sections of 8 µm were obtained using a Leica 
cryostat CM1950 (Leica Biosystems). Before staining, the sections were rehydrated and then incubated with 
blocking solution (1% BSA, 10% FBS, 0.3% Triton X-100, and rat anti-mouse FcγII/III receptor 1:100, in 
PBS) for 1h at room temperature. The sections were incubated overnight at 4
o
C in 100-200 µl of blocking 
solution containing the primary antibodies listed in Supplementary Table 4. Non-conjugated antibodies 
were revealed with secondary antibodies. After staining, nuclei were labeled with DAPI (1 µg/ml) and 
sections mounted in Dako Fluorescence Mounting Medium, covered with cover glass (Heathrow Scientific), 
and stored at 4¡C.  
 
Immunofluorescence staining of cultured cells 
Cells were seeded on glass chamber slides (Lab-Tek) or glass coverslips (Electron Microscopy Sciences) 
coated with 50 µg/ml poly-L-lysine (Sigma). After 16-24h, the cells were treated with drugs or EVs for an 
additional 24h. At the time of analysis, the cells were washed with PBS, fixed with 4% paraformaldehyde for 
20 min, permeabilised with a solution containing 0.1% Triton X-100 in PBS for 10 min, and blocked with 1% 
BSA in PBS for 1h at room temperature. Primary antibodies (Supplementary Table 4) were then applied 
overnight at 4
o
C. In some experiments, Alexa Fluor-488 Phalloidin (Life Technologies, 1:40) was added for 
labelling the actin cytoskeleton. Slides were washed and secondary antibodies applied for 1h in blocking 
solution at the final concentration of 1:200. After washing, cell nuclei were labelled with DAPI (1 µg/ml) or 
DRAQ5 (20 µM, Thermo Fisher Scientific) and the slides mounted.  
 
Duolink staining 
bEnd.3 cells were seeded on poly-L-lysine-coated glass coverslips in a 48-well plate and incubated for 24h 
with PBS, CREMO- or PTX-EVs (50 µg/ml) from 4T1 cells. Cells were then washed with PBS and fixed with 
4% paraformaldehyde for 20 min. After several washes with PBS, cells were permeabilised with 0.3% Triton 
for 20 min. The Duolink PLA technology (Sigma) was then applied to examine physical proximity between 
ANXA6 and p65. Specifically, the Red Starter Kit Mouse/Rabbit was used according to the manufacturerÕs 
instructions. The primary rabbit anti-ANXA6 (Life Technologies, 720161) and mouse anti-p65 (Santa Cruz, 
clone F-6, sc-8008) antibodies were incubated overnight at 1:400 and 1:150, respectively, together with 
Alexa Fluor-488 Phalloidin (Life Technologies, 1:40) for labelling the actin cytoskeleton. 
 
Image acquisition by confocal microscopy 
In order to image immunostained tissue sections and cultured cells, we used a Zeiss LSM700 confocal 
microscope coupled to a high sensitivity Axiocam MRm (B/W) camera. Fluorescent signals from individual 
fluorophores were acquired sequentially from single optical sections, analysed and pseudocoloured using 
the ZEN software (Zeiss) or ImageJ. 
 
Subcellular localization of mCh by immunofluorescence staining and confocal microscopy 
To determine the subcellular localization of mCh in 4T1-mCh cultures exposed to drugs, confocal images 
were analysed using the ImageJ software. For each cell, the lining of the plasma membrane (+/- 0.5 µm) 
was determined manually by visualizing beta-tubulin immunostaining and saved as a region of interest 
(ROI), while the lining of the nucleus was determined according to DAPI staining by applying a Yen 
threshold with the Analyze particle tool of ImageJ. The cytoplasmic area was defined as the area between 
the plasma membrane and the nucleus. mCh signal intensity was calculated in both plasma membrane and 
cytoplasm compartments, and expressed as a ratio.   
 
Quantification of mCh and ANXA6 transfer to ECs 
To study mCh transfer, bEnd.3 cells were seeded in 24-well plates either directly on the plastic (for FACS 
and Western blotting) or on poly-L-lysine-coated glass coverslips (for immunofluorescence staining). Cells 
were then treated with purified EVs (1-200 µg/ml of total protein) or medium conditioned by cultured cancer 
cells (CM). Before use, CM was centrifuged at 500 x g for 5 min; 2000 x g for 5 min; and 4600 x g for 
20xmin, at 4¡C to remove dead cells, debris and large vesicles. bEnd.3 cells were then allowed to grow for 
additional 24h before analysis. Before analysis, the cells were extensively washed with PBS and treated with 
trypsin/EDTA to detach them (FACS), or lysed with RIPA buffer, or fixed with paraformaldehyde 
(immunofluorescence staining).  
 
Chemicals and cytokines 
Cas-BIND Pro Pan Caspase Pro-VAD-FMK (Verget Bioscience) or control DMSO were added to 40-50% 
confluent cells at a final concentration of 10 µM in EV-depleted medium. After 2h, PTX (100 ng/ml) or 
CREMO were added for another 72h. The cell permeant chelator BAPTA-AM (Life Technologies) or control 
DMSO were added to 40-50% confluent cells to a final concentration of 3 µM in EV-depleted medium. After 
2h, PBS, PTX (100 ng/ml), DOX (200 ng/ml) or the appropriate vehicle were applied for another 48h. 
Recombinant human TNFα was purchased from Peprotech and used at 20 ng/ml in complete growth 
medium. 
  
Cell viability and apoptosis assays 
Cell viability was assessed by a WST-1 assay (Roche) according to the manufacturerÕs instructions. Briefly, 
5000 cells were seeded in 96-well plates and treated with drugs as described above. After 72h, 10 µl of 
WST-1 reagent was added to each well and absorbance at 450 nm was measured using a TECAN plate-
reader (TECAN). 
 Cell apoptosis was assessed by FACS analysis of biotin-conjugated AnnexinV (BD Biosciences) and 
7AAD (Sigma), according to the manufacturerÕs instructions. Briefly, 200000 cells were seeded in 6-well 
plates and treated with drugs. After 48h, the cells were trypsinized and transferred to a tube along with the 
conditioned medium. Cells were centrifuged at 2000 rpm, washed with ice-cold PBS, and resuspended in 1x 
binding buffer at a concentration of 10
6 
cells/ml. The cell suspension was then stained with biotin-conjugated 
AnnexinV for 15 min at room temperature, followed by streptavidin-eFluor 450 (eBioscience; 1:100) for 15 
min on ice. After washing, cells were resuspended in 7AAD (1:200) and immediately analysed by FACS. 
 
Gene expression analyses by quantitative polymerase chain reaction (qPCR) 
Small tissue fragments were obtained from the lungs of perfused tumour-free or bearing mice, washed in 
PBS, frozen on dry ice, and stored at Ð80
o
C. Total RNA was purified using miRNeasy Mini kit guidelines 
(Qiagen). RNA was quantified with a NanoDrop ND-2000 and retrotranscribed using SuperScript¨Vilo cDNA 
synthesis kit (Invitrogen). 
 All qPCR reactions were performed using the following TaqMan gene assays: Hprt Mm 01545399-m1, 
B2m Mm 00437762_m1, Gapdh Mm99999915_g1 Angpt2 Mm00545822_m1, Csf1 Mm00432686_m1, Il6 
Mm00446190_m1, Cxcl12 Mm 00445553-m1, Ccr2 Mm04207877_m1, and Ccl2 Mm00441242, all from 
Applied Biosystems/Life Technologies. Each assay was performed in three technical replicates using 10 ng 
of total cDNA per reaction and 2x TaqMAN Universal master mix (Life Technologies). qPCR reactions were 
performed for 40 cycles in standard mode using an ABI7900HT apparatus (Applied Biosystems). Raw data 
were extracted and evaluated using the SDS software v2.4. For the analysis of the results, we calculated the 
average of the median threshold cycle (Ct) of one or two reference genes (Hprt, Gapdh and/or B2m) for 
each sample (reference Ct), as described previously 
66
. 
 
Western blotting 
Cells or purified EVs were lysed in ice-cold RIPA buffer containing Halt protease and phosphatase 
inhibitors (Thermo Fisher Scientific). Conditioned medium (CM) was concentrated using Vivaspin¨ 20 
columns (5000K MW cutoff, Sartorius). Protein concentration was determined by BCA Protein Assay 
Reagent Kit (Thermo Fisher Scientific). Proteins were denatured at 95¡C for 5 minutes with 6x Laemmli 
buffer (Bioworld), or at 90¡C for 10 min with LDS Sample buffer 4x and Reducing agent 10x (both from Life 
Technologies). Unless stated otherwise, matched protein amounts for each sample were analysed in each 
experiment. 
 Proteins (10 to 20 µg) were separated by 12% or 4-12% (gradient) SDS-PAGE (Life Technologies) and 
blotted onto PVDF membranes (Amersham Hybond 0.45 µm, GE Healthcare). Membranes were blocked 
with 5% milk in TBS-T for 24h, incubated with primary antibodies (Supplementary Table 4) for 12 h at 4¡C, 
and then with HRP-conjugated secondary antibodies for 1h at room temperature. Proteins of interest were 
visualized using ECL Western Blotting substrate (Pierce, Rockford, IL, USA) and a Fusion FX7 device 
(Peqlab). In some experiments, PVDF membranes were instead blocked with Odyssey Blocking Buffer (LI-
COR Biosciences), incubated with primary antibodies for 12 h at 4¡C, followed by IRDye 800CW or 680RD-
conjugated secondary antibodies (LI-COR Biosciences) in 0.1% Tween and 0.01% SDS for 1h at room 
temperature. Blots were imaged on the LI-COR Odyssey scanner. 
 
ELISA 
After dissection, lungs were immediately frozen on dry ice and stored at -80
o
C. For protein extraction, lungs 
were washed with ice-cold PBS and minced into small fragments before mechanical homogenization in PBS 
containing Halt phosphatase and protease inhibitors (Thermo Fisher Scientific). After three freeze-thaw 
cycles to break cellular membranes, homogenates were centrifuged at 13000 rpm for 15 min at 4
o
C. To 
measure CCL2, we used the Quantikine Mouse/Rat CCL2/MCP-1 Immunoassay from R&D (MJE00) and 50 
mg of total protein for each reaction. ELISA was performed according to the manufacturerÕs instructions. 
Absorbance was measured using a TECAN Safire2 plate-reader (TECAN). 
 To examine if ANXA6 localizes on the EV surface, we used a homemade ELISA and a polyclonal anti-
ANXA6 antibody (720161, Thermo Fisher Scientific). Antibodies against the endoplasmic reticulum protein 
GP96 (clone 9G10, Enzo) or the extracellular domain of CD81 (clone B-11, Santa Cruz) were used as 
negative and positive control for staining the outer EV surface, respectively. The antibodies were diluted (5 
µg/ml) in ELISA coating solution (Thermo Fisher Scientific) and used for coating a Nunc MaxiSorb 96-well 
plate (Thermo Fisher Scientific). The plate was then blocked with ELISA blocking solution (Thermo Fisher 
Scientific) and washed (two washes with PBS with 0.04% Tween, followed by two with PBS only) before 
adding the EVs (150 µg/ml, in PBS) for an overnight incubation at 4¡C. Acquisition of EV-associated mCh 
fluorescence, before and after four washes with PBS to remove unadsorbed EVs, used a TECAN Safire2 
plate-reader. A final acquisition was performed after the lysis of the EVs with 0.3% Triton in PBS for 2h at 
4¡C and three PBS washes.  
 
EDTA treatment of EVs 
To examine the localization of ANXA6 in EVs, EVs were treated with PBS or EDTA in PBS (1 mM) for 30 
min at 37¡C. After washing three times in PBS, the EVs were loaded onto Vivaspin¨ 500 columns (300000 
MW cutoff, Sartorius) and centrifuged at 4000 x g for 15 min to retain EVs and discharge free 
macromolecules, before Western blotting analysis. 
 
Late endosome enrichment 
Cells were treated with drugs for 24h. After cell homogenization with a 25-gauge needle, we enriched late 
endosomes by continuous density gradient centrifugation 
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. The 25%/HB interface, enriched in late 
endosomes, and the 35%/40.6% interface, enriched in heavier membranes (e.g., endoplasmic reticulum and 
mitochondria), were collected and concentrated by ultracentrifugation (100000 x g for 1h) using a Beckman 
ultracentrifuge. The 40.6% fraction enriched in cytosolic proteins was also collected to concentrate proteins 
with Vivaspin¨ 20 columns (3000K MW cutoff, Sartorius).  
 
NF-kB reporter assay 
Cells were transduced with the NF-kB reporter LV and treated with 10 µg/ml EVs several weeks after 
transduction. Two days post-EV treatment, the cells were trypsinized, washed in EDTA and analysed by 
FACS. To quantitate NF-kB activity, we calculated the fluorescence intensity of both GFP and mCh after 
subtracting the background fluorescence of untransduced cells. In studies involving PTX-EVs, NF-kB activity 
was determined as the ratio between mCh and GFP fluorescence. In studies involving DOX-EVs, NF-kB 
activity was determined from GFP fluorescence, as DOX is fluorescent in the red channel. 
 Liquid chromatography-tandem mass spectrometry (LC-MS/MS) 
EVs (17 µg) of PTX- or CREMO-treated 4T1 cells were directly analysed by LC-MS/MS. EV-derived proteins 
of MDA-MB-231 cells (1 µg) or human plasma (1 µg) were first resolved on a denaturing 4-12% 
polyacrylamide gradient gel. Gel slices were excised in the area predicted to contain ANXA6 (ranging from 
60 to 85 kDa) to elute proteins for LC-MS/MS. 
 To perform LC-MS/MS, we applied a previously published procedure 
68
. Briefly, peptides were desalted 
using StageTips, dried in a vacuum concentrator, and separated by reverse phase chromatography using a 
Dionex Ultimate 3000 RSLC nano UPLC system connected in-line with an Orbitrap Elite (Thermo Fisher 
Scientific). Database search was performed using Mascot 2.5 (Matrix Science) and SEQUEST in Proteome 
Discoverer v.1.4. against a murine or human Uniprot protein database. Data were further processed and 
inspected in ScaffoldTM 4.8.4 (Proteome Software); quantitative values normalized to total spectra were 
used to compare the proteomic profiles. 
 
Plasma isolation from breast cancer patients 
Using an IRB-approved sample collection protocol at the Massachusetts General Hospital Cancer Center, 
subjects were consented for serial venous blood collections. The study was compliant with all relevant 
ethical regulations regarding research involving human participants. Plasma samples were obtained from six 
women diagnosed with invasive breast cancer with histopathologically confirmed tumour stage ranging from 
IA to IIIA; immunohistochemical subtyping and lymph node status of each patient are reported in 
Supplementary Table 2. All subjects had 20 ml of blood collected into Streck tubes prior to initiation of 
neoadjuvant chemotherapy, which consisted of four cycles of every two week dose-dense DOX at 60 mg/m2 
and cyclophosphamide at 600 mg/m
2
 (AC), followed by four cycles of every two week PTX at 175 mg/m
2
. A 
second 10 ml blood sample was collected prior to starting PTX (on the day of the first PTX infusion), and a 
third 10 ml blood sample on the last or second-to-last cycle of PTX.  
 All blood samples were centrifuged at 1600 x g at room temperature for 10 min. The supernatant 
(plasma) was then transferred to one fresh 10 ml centrifuge tube without disturbing the cellular layer, and 
centrifuged at 3000 x g at room temperature for 10 min. The supernatant from the second centrifugation was 
stored into 2 ml pre-labelled cryogenic vials at -70¡C. Before EV isolation, plasma was centrifuged at 10000 
x g for 20 min at 4¡C; one ml of plasma was processed for EV isolation. 
 
Statistics and reproducibility 
Information on the study outline, sample size and statistical analysis is presented in the main text, figures, 
and figure legends. Studies involving independent cohorts of mice were typically performed once, with the 
exceptions stated in the figure legends. Each study was designed to use the minimum number of mice 
required to obtain informative results (i.e., quantitative data suited to statistical analysis) and sufficient 
material for further studies. No specific statistical tests were used to predetermine the sample size. 
 The investigators were not blinded when assessing the results or analysing data. On rare occasions, 
outliers at end-point were excluded by using the ROUT method (GraphPad Prism) to identify outliers. In rare 
cases, selected samples were lost or excluded from specific analyses because of technical flaws during 
sample collection, processing or data acquisition. 
 The number of biological (non-technical) replicates for each experiment is indicated in the figure 
legends. All experiments were repeated independently with similar results. When less than three biological 
replicates were available, statistics were not computed. Data are shown as mean values ± standard error of 
the mean (s.e.m.) for most analyses, with the exception of in vitro studies with a sample size of n=3, in 
which mean values ± standard deviation (s.d.) are reported. In experiments involving animals, each dot in 
the chart represents one mouse or zebrafish embryo. Source data for all experiments are provided in 
Supplementary Table 5. 
 Statistical analysis of the data was performed using the GraphPad Prism software. Statistical analysis 
of differentially expressed proteins in the LC-MS/MS 4T1-EV study was performed using an unpaired two-
tailed t-test implemented in R; P values were adjusted after correcting for false discovery rate using a 
Benjamini-Hochberg method. Statistical analysis of experiments involving more than two experimental 
groups used one-way ANOVA with TukeyÕs correction for multiple comparisons, unless indicated otherwise. 
When the influence of two nominal variables on one measurement variable was examined, a two-way 
ANOVA followed by TukeyÕs or Sidak's correction was applied. Experiments involving two experimental 
groups were analysed by unpaired two-tailed studentÕs t-test with 95% confidence interval, unless indicated 
otherwise.  
 Statistical significance of the data is summarized as follows: *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 
0.0001. Differences among experimental groups were considered significant at P values of less than 0.05. 
Exact P values are provided in all instances, except when P > 0.05 or P < 0.0001. 
 
Reporting summary 
Further information on experimental design is available in the Nature Research Reporting Summary 
linked to this paper. 
 
Data availability 
Uncropped and replicate Western blots not shown in the figures are provided as Supplementary Figure 
9. 
 4T1-EV data have been submitted to the EV-TRACK knowledgebase (EV-TRACK ID: EV180041) 
(Ref. 69). The mass spectrometry proteomics data have been deposited to the ProteomeXchange 
Consortium via the PRIDE partner repository 
70
 with the following dataset identifiers: PXD010362 
(accession) and 10.6019/PXD010362 (DOI) for the 4T1 EV data; and PXD010292 (accession) and 
10.6019/PXD010292 (DOI) for the human EV data. 
 Source data for all graphical representations are provided as Supplementary Table 3 and 
Supplementary Table 5. All other data supporting the findings of this study are available from the 
corresponding authors on request. 
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Supplementary Figure 1 
PTX does not alter the physical features of mammary tumour-derived EVs 
(a) Concentration (mean ± s.e.m.; n=5 acquisitions of one sample/condition) and size distribution of EVs isolated from medium 
conditioned by CREMO- or PTX-treated 4T1 cells, determined by NTA. (b) Western blotting analysis of the indicated proteins in 
material recovered after low-speed (2,000 x g, 2K), medium-speed (4,600 x g, 4.6K) or high-speed (134,000 x g, 134K) centrifugation of 
medium conditioned by 4T1 cells treated as indicated. The experiment was performed once, but additional data on EVs isolated after 
high-speed centrifugation are also shown in Fig. 3d-f, h and Fig. 4c. (c) Correlation between EV protein content and EV concentration, 
measured by BCA and NTA, respectively, in EVs isolated from medium conditioned by 4T1 cells treated as indicated. Four serial 
dilutions and three technical replicates of one sample/condition were measured; the mean of technical replicates is shown. A simple 
linear regression function was used to determine the relationship between the two parameters. The amount of EVs contained in each 
 
 
EV dose administered to mice (15 µg) was determined by extrapolation of the data. (d) Representative TEM images of EVs isolated ex 
vivo from MMTV-PyMT tumours that had been treated in vivo with either CREMO or PTX (see Fig. 2d). Scale bars, 200 nm. The 
experiment was performed once. (e) Concentration (mean ± s.e.m.; n=5 acquisitions of one sample/condition) and size distribution of 
MMTV-PyMT tumour-derived EVs obtained as in (d), determined by NTA. (f) Mode size (mean values ± s.d.; n=3 independent EV 
preparations) of MMTV-PyMT tumour-derived EVs obtained as in (d), determined by NTA. (g) Western blotting analysis of CD9 and 
GAPDH in MMTV-PyMT tumour-derived cells and their EVs. The experiment was performed once. 
Source data are shown in Supplementary Table 5 and unprocessed blots in Supplementary Fig. 9. 
 
 
 
Supplementary Figure 2 
PTX enhances EV release from cancer cells in vitro and in tumour-bearing mice 
(a) WST-1 assay-based viability of 4T1 cancer cells (mean ± s.d.; n=6 independent cell cultures/condition) relative to untreated cells 
(UT). (b) mCh mean fluorescence intensity (MFI; mean ± s.e.m.; n=3 independent cell cultures/condition) in medium conditioned by 
 
 
4T1-mCh cells treated for 72h as indicated. Statistical analysis by one-way ANOVA with TukeyÕs multiple comparison test. (c) Protein 
content by BCA (left y axis) and concentration by NTA (right y axis) in EVs (mean ± s.d.; n=3 independent cell cultures/condition) from 
MDA-MB-231 cells treated for 72h with CREMO or PTX. Statistical analysis by unpaired two-tailed StudentÕs t-test. (d) Absolute mCh 
MFI (mean ± s.e.m.) in plasma of tumour-free (n=6), 4T1 tumour-bearing (n=10), and 4T1-mCh tumour-bearing Rag1
-/- 
mice treated 
with CREMO (n=12) or PTX (n=14); two independent experiments combined (left panel). Statistical analysis as in (b). Right panel 
shows data after subtracting background fluorescence (ΔMFI; mean ± s.e.m.) and normalizing the results to tumour weight. Statistical 
analysis as in (c). (e) Correlation between tumour weight and mCh ΔMFI in plasma of mice shown in (d), right panel. The Pearson 
correlation coefficient (r) is indicated. (f) mCh ΔMFI (mean ± s.e.m.) in plasma of 4T1-mCh/HER2 tumour-bearing Rag1
-/- 
mice (PBS, 
n=7; PTX, n=9; CREMO, n=8). Statistical analysis as in (b). (g) Correlation between mCh MFI and protein concentration by BCA (left) 
or particle concentration by NTA (right) in EVs from medium conditioned by 4T1-mCh cells. Five (left) or four (right) serial dilutions and 
three technical replicates of one sample/condition were measured; the mean of technical replicates is shown. A simple linear regression 
function was used to extrapolate relationship between the two variables. (h) Western blotting analysis of the indicated proteins in EVs 
or EV-depleted, concentrated conditioned medium (CM) from 4T1, 4T1-mCh or PyMT-IK1-mCh cells. EVs and CM were recovered 
after high-speed (134,000 x g) centrifugation. Each experiment was performed once. (i) mCh MFI and protein concentration by BCA 
(left) or particle concentration by NTA (right) in EVs isolated from medium conditioned by 4T1-mCh cells. Six EV fractions were 
obtained by sucrose fractionation of purified EVs. Three technical replicates of each EV fraction/condition were measured; the mean of 
technical replicates is shown. (j) mCh MFI (mean ± s.e.m.) in plasma of 4T1 (n=3) or 4T1-mCh (n=7) tumour-bearing Rag1
-/- 
mice. 
Plasma was incubated with or without proteinase K (PK). Statistical analysis as in (b). (k) mCh MFI (mean ± s.e.m.) of recombinant 
mCh incubated with or without PK in either water (n=3 independent experiments/condition) or mouse plasma (n=4). Data show 
percentage values over untreated (-PK) samples. Statistical analysis by two-way ANOVA with SidakÕs multiple comparison test. 
Source data are shown in Supplementary Table 5 and unprocessed blots in Supplementary Fig. 9. 
 
 
 
Supplementary Figure 3 
PTX increases cancer cell-derived EV release in a RAB27A-dependent and apoptosis-independent manner 
(a, b) FACS of 4T1 cells treated for 48h with CREMO or PTX (n=3 independent cell cultures/condition) in the presence of the pan-
caspase inhibitor CAS-BIND Pro or DMSO (vehicle). Panel (a) shows representative FACS dot plots of cells stained for ANXA5 and 
7AAD to identify early apoptotic (ANXA5
+
7AAD
Ð
) cells. Panel (b) shows quantitative data (mean ± s.d.). Statistical analysis by one-way 
 
 
ANOVA with TukeyÕs multiple comparison test. (c) mCh MFI (left y axis) and concentration by NTA (right y axis) of EVs (mean ± s.d.; 
n=3 independent cell cultures/condition) from 4T1-mCh cells treated for 72h with PTX in the presence of CAS-BIND Pro or DMSO 
(vehicle). Statistical analysis by unpaired two-tailed StudentÕs t-test. (d) Western blotting analysis of RAB27A and GAPDH in Rab27a-
KO or WT 4T1-mCh cells. The experiment was performed once. (e-g) mCh MFI (left y axis) and concentration by NTA (right y axis) of 
EVs (mean ± s.d.; n=3 independent cell cultures/condition) from Rab27a-KO or WT 4T1-mCh cells treated as indicated. Statistical 
analysis as in (c). (h) Subcellular localization of mCh in 4T1-mCh cells treated as indicated. Panels above show representative images 
of cells stained with anti-beta-tubulin antibody (green) and DAPI (blue); mCh signal (magenta) was acquired as direct fluorescence. 
Scale bars, 10 µm. Panels below show ratio between membrane and cytoplasm-associated mCh signal (mean ± s.e.m.; n=4 randomly 
selected image fields, each containing at least 120 cells, per condition). Statistical analysis as in (c). Note increased localization of mCh 
to plasma membranes after PTX in RAB27A-proficient cells. (i) mCh MFI (mean ± s.d.; n=5 independent cell cultures/condition) of EVs 
from 4T1-mCh cells treated for 72h as indicated. Statistical analysis as in (c). (j) mCh MFI (left y axis) and concentration by NTA (right y 
axis) of EVs (mean ± s.d.; n=3 independent cell cultures/condition) from 4T1-mCh cells treated for 72h as indicated. Statistical analysis 
as in (c). (k) Protein content by BCA (left y axis) and concentration by NTA (right y axis) in EVs (mean ± s.d.; n=3 independent cell 
cultures/condition) from MDA-MB-231 cells treated for 72h as indicated. Statistical analysis as in (c). 
Source data are shown in Supplementary Table 5 and unprocessed blots in Supplementary Fig. 9. 
 
 
 
Supplementary Figure 4 
PTX promotes loading of ANXA6 into bona fide cancer cell-derived EVs 
(a) Western blot analysis of the indicated proteins in 4T1-mCh EVs after fractionation by sucrose density gradient centrifugation. Note 
the association of ANXA6 with EV fractions with a density ranging from 1.12 to 1.17 g/ml. One representative experiment is shown of 
two performed. (b) Protein band intensity (n=2 independent experiments, one of which is shown in (a) above) in the indicated EV 
fractions. For each protein, the relative signal intensity in each fraction is indicated as percentage of the total signal in all fractions. The 
 
 
line connects mean values. (c) ELISA assay showing the binding of antibodies against CD81, GP96 or ANXA6 to CREMO-EVs and 
PTX-EVs. Note the limited binding of an anti-ANXA6 antibody to either EV preparation after washing, compared to the anti-CD81 
antibody. Results show one EV sample per condition and the mean of three technical replicates. (d) Western blotting analysis of 
ANXA6, GAPDH and CD81 in CREMO-EV and PTX-EV incubated with EDTA or PBS. Note that EDTA did not reduce ANXA6 signal in 
EVs, indicating intra-vesicular localization. One representative experiment is shown of three performed. (e) Viability of primary mouse 
bone marrow dendritic cells (BMDCs; mean ± s.d.; n=3 independent cell cultures) treated as indicated for 72h. Statistical analysis by 
one-way ANOVA with TukeyÕs multiple comparison test. (f) Western blotting analysis of ANXA6, GAPDH and CD81 in CREMO-EV and 
PTX-EV isolated from BMDCs. One representative experiment is shown of two performed. (g) Viability of primary mouse embryonic 
fibroblasts (MEFs; mean ± s.d.; n=4 independent cell cultures) treated as indicated for 72h. (h) Western blotting analysis of ANXA6, 
GAPDH and CD81 in CREMO-EV and PTX-EV isolated from MEFs. The experiment was performed once. (i) Western blotting analysis 
of ANXA6 and GAPDH in Anxa6-WT (parental) and Anxa6-KO 4T1 cells. The experiment was performed once. (j) Quantification of 
Oregon Green 488 PTX (left) and autofluorescent DOX (right) in EVs (mean ± s.d.; n=3 independent cell cultures/condition) from 
Anxa6-WT or Anxa6-KO 4T1 cells. (k) Quantification of Oregon Green 488 PTX (left) and autofluorescent DOX (right) in EVs from 
MDA-MB-231, PyMT-IK1 and 4T1 cells. Data show mean values of three serial dilutions per sample. 
Source data are shown in Supplementary Table 5 and unprocessed blots in Supplementary Fig. 9. 
! !
 
 
 
 
Supplementary Figure 5 
EV transfer to ECs induces a drug-independent pro-inflammatory response 
(a) Representative confocal images of bEnd.3 cells either untreated or incubated for 24h with PTX-EVs (50 µg/ml) from 4T1-mCh cells. 
Cells were stained with an anti-mCh antibody (red), AF488-conjugatd phalloidin (white) and DRAQ5 to reveal nuclei (cyan). Orthogonal 
projections from a z-stack acquisition are shown. Scale bars 10 µm. One image per condition is shown, representative of 3 independent 
experiments. (b) FACS analysis of bEnd.3 cells treated for 24h with increasing doses of EVs isolated from 4T1-mCh cells. One 
representative sample per condition is shown. (c, d) FACS analysis of mCh in bEnd.3 cells incubated with conditioned medium (CM; c) 
or purified mCh
+
 EVs (d) from 4T1-mCh (left panels) or PyMT-IK1-mCh (right panels) cells treated as indicated. mCh-negative 4T1 and 
PyMT-IK1 cells were used as controls. Data show mCh MFI (mean ± s.d.; n=3 independent cell cultures/condition). Statistical analysis 
by one-way ANOVA with TukeyÕs multiple comparison test. (e) FACS analysis of mCh in bEnd.3 cells incubated with conditioned 
medium (CM) of Anxa6-WT or Anxa6-KO 4T1-mCh cells treated as indicated. Data show mCh MFI (mean ± s.d.; n=3 independent cell 
cultures/condition). Statistical analysis by two-way ANOVA with SidakÕs multiple comparison test. 
Source data are shown in Supplementary Table 5. 
 
 
 
Supplementary Figure 6 
ANXA6 induces NF-kB activation and Ccl2 upregulation in bEnd.3 cells 
 
 
(a) Western blotting analysis of ANXA6 and GAPDH in Anxa6-WT and KO bEnd.3 cells. The experiment was performed once. (b) 
Western blotting analysis of ANXA6, mCh and beta-actin (ACTB) in untreated Anxa6-WT 4T1 and bEnd.3 cells, as well as untreated or 
EV-treated Anxa6-KO bEnd.3 cells. One representative experiment of two performed; additional data are shown in Fig. 7d. (c) Duolink 
staining of bEnd.3 cells. Upper panel shows ANXA6/p65 proximity expressed as number of dots/cell (mean ± s.e.m.; n=8 randomly 
selected images with at least 12 cells each); unstained Anxa6-WT bEnd.3 cells (n=3 randomly selected images with at least 12 cells 
each) were used as negative control. Statistical analysis by one-way ANOVA with TukeyÕs multiple comparison test. Bottom panels 
show representative images; nuclei are stained with DAPI (blue), actin cytoskeleton with phalloidin (red). Scale bar, 30 µm. (d) Duolink 
staining of Anxa6-KO bEnd.3 cells treated as indicated. Images show ANXA6/p65 proximity (white dots); nuclei are stained with DAPI 
(blue), actin cytoskeleton with phalloidin (red). Scale bars, 30 µm. Results are representative of two independent experiments. (e) NF-
kB activity in bEnd.3 cells. Left panel shows the NF-kB reporter lentiviral vector (LV). Note that red fluorescence of LV-encoded mCh is 
much stronger than the red fluorescence of EV-transferred mCh. Therefore, EV-derived mCh does not affect quantification of NF-kB 
reporter activity. Right panel shows representative FACS dot plots of bEnd.3 cells either untransduced (UT) or transduced with the NF-
kB reporter LV before incubation with or without TNFα for 48h. Transduced (mCh
+
) cells are gated and analysed for GFP expression. 
For quantitative data, see (f). (f) NF-kB activity determined by FACS analysis of transduced bEnd.3 cells incubated with or without 
TNFα for 24h. NF-kB activity is shown as GFP MFI in transduced (mCh
+
) cells (mean ± s.d.; n=3 independent cell cultures/condition). 
Statistical analysis by two-way ANOVA with TukeyÕs multiple comparison test. (g-i) qPCR analysis of Ccl2 (g), Csf1 (h) and Cxcl12 (i) in 
bEnd.3 cells incubated with or without TNFα for 5h (mean ± s.d.; n=3 independent cell cultures/condition). Statistical analysis as in (f). 
Source data are shown in Supplementary Table 5 and unprocessed blots are shown in Supplementary Fig. 9. 
! !
 
 
 
Supplementary Figure 7 
Chemotherapy-elicited EVs display broad cellular tropism in tumour-bearing mice 
(a) FACS analysis of mCh
+
CD45
+
CD11b
+
Ly6G
Ð
 macrophages/monocytes (mac/mono; mean ± s.e.m.; relative to viable lung-derived 
cells) in the lungs of 4T1 (n=6) or 4T1-mCh (CREMO, n=8; PTX, n=9) tumour-bearing Rag1
Ð/Ð
 mice treated as indicated. Statistical 
analysis by one-way ANOVA with TukeyÕs multiple comparison test. The right panels show representative FACS dot plots. (b) FACS 
analysis of mCh
+
CD45
+
CD11b
+
Ly6G
Ð
 mac/mono (mean ± s.e.m.; relative to viable lung-derived cells) in the lungs of 4T1 (n=4) or 4T1-
mCh/HER2 (PBS, n=7; CREMO, n=8; PTX, n=9) tumour-bearing Rag1
Ð/Ð
 mice treated as indicated. Statistical analysis by one-way 
ANOVA with TukeyÕs multiple comparison test. (c) qPCR analysis of Il6 in whole lung tissue (mean ± s.e.m.) of FVB/n mice that 
received either CREMO-EV (n=10) or PTX-EV (n=9). Statistical analysis by unpaired two-tailed StudentÕs t-test. (d) qPCR analysis of 
Il6 (mean ± s.e.m.) in FACS-sorted lung myeloid cells of FVB/n mice that received either CREMO-EV or PTX-EV (n=5 mice per group, 
except Mac/CREMO-EV where n=4). Statistical analysis by two-way ANOVA with TukeyÕs multiple comparison test. (e) FACS analysis 
of mCh
+
CD31
+
CD45
Ð 
liver ECs (mean ± s.e.m.; relative to viable liver-derived cells) in the livers of 4T1 (n=6) or 4T1-mCh (CREMO, 
n=7; PTX, n=9) tumour-bearing Rag1
Ð/Ð
 mice treated as indicated. Statistical analysis by one-way ANOVA with TukeyÕs multiple 
comparison test. The right panels show representative FACS dot plots. (f) Representative confocal immunofluorescence images of anti-
CD31 EC (green) and anti-mCh (magenta) immunostaining of liver sections from 4T1-mCh tumour-bearing mice treated as in (e); nuclei 
are stained with DAPI (blue). Scale bars, 10 µm. 
Source data are shown in Supplementary Table 5. 
 
 
 
 
Supplementary Figure 8 
ANXA6 is detected in circulating EVs of breast cancer patients undergoing neoadjuvant therapy 
LC-MS/MS quantification of ANXA6 in EVs isolated from the plasma of six breast cancer patients before chemotherapy (pre-treatment), 
after AC (anthracycline (DOX)/cyclophosphamide) and after PTX. The data show the number of exclusive ANXA6 peptides (left) and 
the quantitative values after normalization to the total proteins identified in the same area of the gel (right). 
Source data are shown in Supplementary Table 3. 
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Supplementary Figure 9 
Unprocessed blots 
Unprocessed and uncropped blots for all Western blotting data reported in the main and supplementary figures of this study. 
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Supplementary Table 1 
Protein quantification in CREMO-EV and PTX-EV (n=6 independent EV preparations per condition) isolated from 4T1 cells, 
determined by LC-MS/MS analysis 
The table shows number of peptides per protein (minimum number: 4). Statistical analysis by unpaired two-tailed t-test; p-values 
adjusted after correcting for a false discovery rate using a Benjamini-Hochberg method. 
!
Supplementary Table 2 
Medical record of breast cancer patients 
The table shows clinical data for the patients whose EVs were analysed in the study. 
!
Supplementary Table 3 
LC-MS/MS analysis of EVs in the plasma of breast cancer patients 
The table shows time schedule of each blood collection and associated LC-MS/MS values, obtained as number of exclusive ANXA6 
peptides (top) or normalized quantitative values (bottom). 
!
Supplementary Table 4 
List of antibodies used in flow cytometry (FC), immunofluorescence (IF), Western blotting (WB) and ELISA analyses 
The table shows a comprehensive list of antibodies used in the study. 
!
Supplementary Table 5 
Statistics Source Data 
Numerical values for all data shown in the main and supplementary figures. 
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